<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Methotrexate for psoriatic arthritis - Wilsdon, TD - 2019 | Cochrane Library</title> <meta content="Methotrexate for psoriatic arthritis - Wilsdon, TD - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012722.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Methotrexate for psoriatic arthritis - Wilsdon, TD - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012722.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012722.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Methotrexate for psoriatic arthritis" name="citation_title"/> <meta content="Tom D Wilsdon" name="citation_author"/> <meta content="Royal Adelaide Hospital and University of Adelaide" name="citation_author_institution"/> <meta content="tom.d.wilsdon@gmail.com" name="citation_author_email"/> <meta content="Samuel L Whittle" name="citation_author"/> <meta content="The Queen Elizabeth Hospital and University of Adelaide" name="citation_author_institution"/> <meta content="Tilenka RJ Thynne" name="citation_author"/> <meta content="Flinders Medical Centre and Flinders University" name="citation_author_institution"/> <meta content="Arduino A Mangoni" name="citation_author"/> <meta content="Flinders Medical Centre and Flinders University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012722.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012722.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012722.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012722.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Antirheumatic Agents [*administration &amp; dosage, adverse effects]; Dermatologic Agents [*administration &amp; dosage, adverse effects]; Methotrexate [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012722.pub2&amp;doi=10.1002/14651858.CD012722.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012722\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012722\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","pl","fr","fa","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012722.pub2",title:"Methotrexate for psoriatic arthritis",firstPublishedDate:"Jan 18, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012722.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012722.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012722.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012722.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012722.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012722.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012722.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012722.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012722.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012722.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9002 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012722.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0291"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-sec-0255"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/appendices#CD012722-sec-0296"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/table_n/CD012722StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/table_n/CD012722StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Methotrexate for psoriatic arthritis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#CD012722-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Tom D Wilsdon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#CD012722-cr-0003">Samuel L Whittle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#CD012722-cr-0004">Tilenka RJ Thynne</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information#CD012722-cr-0005">Arduino A Mangoni</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information/en#CD012722-sec-0303">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012722.pub2">https://doi.org/10.1002/14651858.CD012722.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012722-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012722-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012722-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012722-abs-0001" lang="en"> <section id="CD012722-sec-0001"> <h3 class="title" id="CD012722-sec-0001">Background</h3> <p>Psoriatic arthritis is an inflammatory disease associated with joint damage, impaired function, pain, and reduced quality of life. Methotrexate is a disease‐modifying anti‐rheumatic drug (DMARD) commonly prescribed to alleviate symptoms, attenuate disease activity, and prevent progression of disease. </p> </section> <section id="CD012722-sec-0002"> <h3 class="title" id="CD012722-sec-0002">Objectives</h3> <p>To assess the benefits and harms of methotrexate for psoriatic arthritis in adults.</p> </section> <section id="CD012722-sec-0003"> <h3 class="title" id="CD012722-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, the WHO International Clinical Trials Registry Platform, and www.clinicaltrials.gov for relevant records. We searched all databases from inception to 29 January 2018. We handsearched included articles for additional records and contacted study authors for additional unpublished data. We applied no language restrictions. </p> </section> <section id="CD012722-sec-0004"> <h3 class="title" id="CD012722-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) and quasi‐RCTs that compared methotrexate versus placebo, or versus another DMARD, for adults with psoriatic arthritis. We reported on the following major outcomes: disease response (measured by psoriatic arthritis response criteria (PsARC)), function (measured by the Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ)), health‐related quality of life, disease activity (measured by disease activity score (28 joints) with erythrocyte sedimentation rate (DAS28‐ESR)), radiographic progression, serious adverse events, and withdrawals due to adverse events. </p> </section> <section id="CD012722-sec-0005"> <h3 class="title" id="CD012722-sec-0005">Data collection and analysis</h3> <p>Two review authors independently reviewed search results, assessed risk of bias, extracted trial data, and assessed the quality of evidence using the GRADE approach. We undertook meta‐analysis only when this was meaningful. </p> </section> <section id="CD012722-sec-0006"> <h3 class="title" id="CD012722-sec-0006">Main results</h3> <p>We included in this review eight RCTs conducted in an outpatient setting, in Italy, the United Kingdom, the United States of America, China, Russia, and Bangladesh. Five studies compared methotrexate versus placebo, and four studies compared methotrexate versus other DMARDs. The average age of participants varied across studies (26 to 52 years), as did the average duration of psoriatic arthritis (one to nine years). Doses of methotrexate varied from 7.5 mg to 25 mg orally per week, but most studies administered approximately 15 mg or less orally per week. Risk of bias was generally unclear or high across most domains for all studies. We considered only one study to have low risk of selection and detection bias. The main study informing results of the primary comparison (methotrexate vs placebo up to six months) was at low risk of bias for all domains except attrition bias and reporting bias. </p> <p>We restricted reporting of results to the comparison of methotrexate versus placebo for up to six months. Low‐quality evidence (downgraded due to bias and imprecision) from a single study (221 participants; methotrexate dose 15 mg orally or less per week) informed results for disease response, function, and disease activity. Disease response, measured by the proportion who responded to treatment according to PsARC (response indicates improvement), was 41/109 in the methotrexate group and 24/112 in the placebo group (risk ratio (RR) 1.76, 95% confidence interval (CI) 1.14 to 2.70). This equates to an absolute difference of 16% more responders with methotrexate (4% more to 28% more), and a number needed to treat for an additional beneficial outcome (NNTB) of 6 (95% CI 5 to 25). Mean function, measured by the HAQ (scale 0 to 3; 0 meaning no functional impairment; minimum clinically important difference 0.22), was 1.0 points with placebo and 0.3 points better (95% 0.51 better to 0.09 better) with methotrexate; absolute improvement was 10% (3% better to 17% better), and relative improvement 30% (9% better to 51% better). Mean disease activity as measured by the DAS28‐ESR (scale of 0 to 10; lower score means lower disease activity; minimum clinically important difference unknown) was 3.8 points in the methotrexate group and 4.06 points in the placebo group; mean difference was ‐0.26 points (95% CI ‐0.65 to 0.13); absolute improvement was 3% (7% better to 1% worse), and relative improvement 6% (16% better to 3% worse). </p> <p>Low‐quality evidence (downgraded due to risk of bias and imprecision) from three studies (n = 293) informed our results for serious adverse events and withdrawals due to adverse events. Due to low event rates, we are uncertain if methotrexate results show increased risk of serious adverse events or withdrawals due to adverse events compared to placebo. Results show 1/141 serious adverse events in the methotrexate group and 4/152 in the placebo group: RR 0.26 (95% CI 0.03 to 2.26); absolute difference was 2% fewer events with methotrexate (5% fewer to 1% more). In all, 9/141 withdrawals in the methotrexate group were due to adverse events and 7/152 in the placebo group: RR 1.32 (95% CI 0.51 to 3.42); absolute difference was 1% more withdrawals (4% fewer to 6% more). </p> <p>One study measured health‐related quality of life but did not report these results. No study measured radiographic progression. </p> </section> <section id="CD012722-sec-0007"> <h3 class="title" id="CD012722-sec-0007">Authors' conclusions</h3> <p>Low‐quality evidence suggests that low‐dose (15 mg or less) oral methotrexate might be slightly more effective than placebo when taken for six months; however we are uncertain if it is more harmful. Effects of methotrexate on health‐related quality of life, radiographic progression, enthesitis, dactylitis, and fatigue; its benefits beyond six months; and effects of higher‐dose methotrexate have not been measured or reported in a randomised placebo‐controlled trial. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012722-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012722-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012722-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD012722-abs-0012">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012722-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012722-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012722-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012722-abs-0004" lang="en"> <h3>Methotrexate for psoriatic arthritis</h3> <p><b>Background</b> </p> <p>Psoriatic arthritis is an inflammatory condition that causes painful, swollen, and stiff joints, along with painful tendons and swollen fingers and toes. It is associated with psoriasis ‐ a disease of the skin or nails. If severe, rheumatologists prescribe methotrexate, a disease‐modifying anti‐rheumatic drug (DMARD), to improve symptoms and prevent worsening. Other DMARDs might include leflunomide, ciclosporin A, sulfasalazine, and gold (although gold treatment is rarely used). </p> <p><b>Review question</b> </p> <p>We aimed to assess the benefits and harms of methotrexate compared with placebo (a fake drug) or similar drugs for adults with psoriatic arthritis. Methotrexate compared with placebo was the primary comparison. Major outcomes were disease response (number of patients with a positive response to treatment), function, health‐related quality of life, disease activity, radiographic progression (bone damage over time as seen on X‐rays), serious adverse events (side effects requiring hospital admission, necessitating intensive therapy, causing permanent disability or death), and withdrawals due to adverse events (side effects that cause people to stop taking the treatment). </p> <p><b>Search date</b> </p> <p>We searched for evidence up to 29 January 2018.</p> <p><b>Study characteristics</b> </p> <p>We included eight studies published between 1964 and 2014. All studies involved people from rheumatology clinics. Studies were conducted in Italy, United Kingdom, United States of America, China, Russia, and Bangladesh. Five studies compared methotrexate against placebo (345 people), and four studies compared methotrexate against another DMARD (leflunomide (61 people), ciclosporin A (35 people), gold (30 people), and sulfasalazine (24 people)). The average age of people included in these studies varied from 26 to 52 years. The average duration of psoriatic arthritis ranged from one to nine years. The dose of methotrexate consisted of 7.5 mg to 25 mg orally, but for most studies, 15 mg was given orally per week. In most western countries, a dose of 15 mg to 20 mg orally per week is normally used in routine practice. </p> <p><b>Key results</b> </p> <p>After six months of treatment, comparison with placebo (a fake drug) showed that methotrexate resulted in the following (note that one study measured but did not report quality of life, and no studies measured radiographic progression). </p> <p>Proportion who responded to treatment as measured by the Psoriatic Arthritis Response Criteria </p> <p>16% more people, or 16 more people out of 100, improved with treatment (4% more to 28% more) </p> <p>37 out of 100 people taking methotrexate improved</p> <p>21 out of 100 people taking placebo improved</p> <p>Function (lower scores mean better function) </p> <p>Function was improved by 10% (ranging from 3% better to 17% better), or by 0.30 points (ranging from 0.09 better to 0.51 better) on a 0 to 3 scale (this is expected to be meaningful to patients) </p> <p>People taking methotrexate rated their function as 0.7 point</p> <p>People taking placebo rated their function as 1.0 point</p> <p>Disease activity (lower scores mean less active disease) </p> <p>Disease activity improved by 3% (7% better to 1% worse), or by 0.26 points (0.65 better to 0.13 worse) on a 0 to 10 scale </p> <p>People taking methotrexate had a disease activity score of 3.8 points</p> <p>People taking placebo had a disease activity score of 4.06 points</p> <p>Serious adverse events (more events mean more harm) </p> <p>2% fewer people, or two fewer people out of 100 (5% fewer to 1% more), reported a serious adverse event with methotrexate </p> <p>One person out of 100 people taking methotrexate had a serious adverse event</p> <p>Three out of 100 people taking placebo had a serious adverse event</p> <p>Withdrawals due to adverse events (more events means more harm) </p> <p>1% more people, or one more person out of 100 (4% fewer to 6% more), withdrew from treatment with methotrexate </p> <p>Six out of 100 people taking methotrexate withdrew</p> <p>Five out of 100 people taking placebo withdrew</p> <p><b>Quality of the evidence</b> </p> <p>Low‐quality evidence suggests that methotrexate might lead to slightly greater benefit than placebo for some outcomes (e.g. improving function) but may be no better than placebo for other outcomes (e.g. reducing disease activity). We assessed the quality of the evidence as low due to flawed trial design and imprecision (some results are meaningful to patients and some are not). We are uncertain whether methotrexate causes more harm than placebo due to the small number of reported events. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012722-sec-0291" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-sec-0291">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-sec-0380">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012722-sec-0291"></div> <h3 class="title" id="CD012722-sec-0292">Implications for practice</h3> <section id="CD012722-sec-0292"> <p>Low‐quality evidence suggests that low‐dose oral methotrexate may be more effective than placebo when taken for six months in terms of disease response (PsARC), function, pain, and patient and physician global assessments of disease activity. The effect size for each of these outcomes is small. Research shows no clinically important differences with respect to disease response (ACR20), disease activity (DAS28‐ESR), tender and swollen joint counts, or skin disease. Methotrexate is generally well tolerated in this population. Neither effects of methotrexate on health‐related quality of life, radiographic progression, enthesitis, dactylitis, and fatigue, and its efficacy beyond six months, nor effects of higher‐dose methotrexate have been adequately studied in a placebo‐controlled trial. </p> <p>With the exception of leflunomide, head‐to‐head data are inadequate to inform comparison versus other DMARDs, including biologic DMARDs. Data comparing methotrexate versus leflunomide are of very low quality, such that we do not believe they provide clinically meaningful information, and we do believe they should be interpreted and applied with extreme caution. Very low‐quality evidence suggests that methotrexate may be as effective as leflunomide when taken for six months and is generally well tolerated, although very few adverse events have been reported and its comparative safety is uncertain. The comparative efficacy of methotrexate in terms of health‐related quality of life, disease activity, radiographic progression, enthesitis, dactylitis, and fatigue, along with its efficacy beyond six months, has not been studied in a placebo‐controlled trial. </p> </section> <h3 class="title" id="CD012722-sec-0293">Implications for research</h3> <section id="CD012722-sec-0293"> <p>Studies included in this review were at unclear or high risk of bias for at least one domain, and they provided evidence of low or very low quality. The certainty of these results could be enhanced by additional high‐quality studies of sufficient sample size. Selection of participants using validated classification criteria, such as the CASPAR criteria, would ensure a homogeneous population for future study comparisons. Several outcomes require evaluation for more complete assessment of efficacy (e.g. quality of life, radiographic progression, enthesitis, dactylitis) and could be informed by the latest OMERACT recommendations (<a href="./references#CD012722-bbs2-0099" title="OrbaiA‐M , deWitM , MeasePJ , DuffinKC , ElmamounM , TillettW , et al. Updating the Psoriatic Arthritis (PsA) Core Domain Set: a report from the PsA Workshop at OMERACT 2016. Journal of Rheumatology2017;44:1522‐8. [DOI: 10.3899/jrheum.160904] ">Orbai 2017</a>). A longer duration of follow‐up would also be useful to clinicians. Finally, dose‐dependent efficacy remains underexplored. Given the greater bioavailability of methotrexate at doses above 15 mg when administered parenterally rather than orally (<a href="./references#CD012722-bbs2-0077" title="HamiltonRA , KremerJM . Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. British Journal of Rheumatology1997;36(1):86‐90. [PUBMED: 9117183] ">Hamilton 1997</a>; <a href="./references#CD012722-bbs2-0105" title="SchiffMH , JaffeJS , FreundlichB . Head‐to‐head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug‐exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Annals of the Rheumatic Diseases2014;73(8):1549‐51. [DOI: 10.1136/annrheumdis‐2014‐205228] ">Schiff 2014</a>), studies utilising subcutaneous or intramuscular administration of methotrexate above 15 mg weekly might provide a suitable method for exploring dose‐dependent efficacy. Further placebo‐controlled trials of methotrexate for psoriatic arthritis would offer an ideal way to resolve this question, although ethical considerations may mean that this trial design is impractical. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012722-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012722-sec-0029"></div> <div class="table" id="CD012722-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methotrexate compared to placebo for psoriatic arthritis (up to six months)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methotrexate compared to placebo for psoriatic arthritis (up to six months)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriatic arthritis<br/> <b>Setting:</b> rheumatology clinics (outpatient setting)<br/> <b>Intervention:</b> methotrexate (oral ≤ 15 mg per week)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methotrexate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease response<br/> assessed with PsARC (response event indicates improvement)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>377 per 1000<br/> (244 to 579) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.76<br/> (1.14 to 2.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 16% more responded to treatment with methotrexate (4% more to 28% more); relative change ‐ 76% more responded to treatment with methotrexate (14% more to 170% more) </p> <p>NNTB 6 (5 to 25)</p> <p>When using imputed values, study authors calculated OR 1.77 (95% CI 0.97 to<br/> 3.23)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Function<br/> assessed with HAQ<br/> Scale from 0 to 3 (0 shows no functional impairment)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HAQ score was 1.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean difference in HAQ score was 0.3 lower<br/> (0.51 lower to 0.09 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute change ‐ 10% better with methotrexate (3% better to 17% better); relative change ‐ 30% with methotrexate (95% CI 9% to 51% improvement)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured in one study but reported as abstract only; data for extraction could not be obtained (personal communication) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease activity<br/> assessed with DAS28‐ESR<br/> Scale from: 0 to 10 (0 shows no disease activity)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean DAS28‐ESR was 4.06</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean difference in DAS28‐ESR was 0.26 lower<br/> (0.65 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement ‐ 3% better with methotrexate (7% better to 1% worse); relative improvement ‐ 6% better with methotrexate (16% better to 3% worse)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiographic progression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (SAEs)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/> (0.03 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 2% fewer events with methotrexate (5% fewer to 1% more); relative difference ‐ 74% fewer (97% fewer to 116% more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events (WAEs) assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/> (23 to 158) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.32<br/> (0.51 to 3.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 1% more events with methotrexate (4% fewer to 6% more); relative difference ‐ 32% more events with methotrexate (49% fewer to 242% more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; DAS28‐ESR: disease activity score (28 joints) with erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire for Rheumatoid Arthritis; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; PsARC: Psoriatic Arthritis Response Criteria; RCT: randomised controlled trial; RR: risk ratio; SAEs: serious adverse events; WAEs: withdrawals due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to risk of bias: judged as unclear or high risk in at least one study. </p> <p><sup>b</sup>Downgraded due to imprecision: low numbers of events with confidence intervals including potentially clinically meaningless benefits. </p> <p><sup>c</sup>Study authors did not report summary data from the ITT population. We assumed that missing participants had no response, and we calculated the ITT analysis using the number randomised. </p> <p><sup>d</sup>Relative changes calculated as absolute change (mean difference) divided by mean at baseline in the placebo group (values were 1.0 on 0 to 3 HAQ; 4.06 on 0 to 10 DAS28‐ESR). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012722-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriatic arthritis<br/> <b>Setting:</b> rheumatology clinics (outpatient setting)<br/> <b>Intervention:</b> methotrexate (oral 7.5 mg to 25 mg per week)<br/> <b>Comparison:</b> other DMARDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other DMARDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methotrexate (any dose)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease response (leflunomide)<br/> assessed with ACR50<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>813 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>853 per 1000<br/> (626 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05<br/> (0.77 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 4% more responders with methotrexate (22% fewer to 31% more); relative change ‐ 5% more responders (23% fewer to 45% more). NNTB not calculated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Function (leflunomide)<br/> assessed with HAQ<br/> Scale from 0 to 3<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HAQ score for leflunomide was 0.17</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean difference in HAQ score for leflunomide was 0.13 lower<br/> (0.23 lower to 0.03 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement ‐ 4% better with methotrexate (1% better to 8% better); relative improvement ‐ 76% better with methotrexate (18% to 135% improvement)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured by any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease activity ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured by any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiographic progression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured by any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (leflunomide)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference and risk ratio could not be calculated due to zero events in both arms. Direction and magnitude of the true effect remain uncertain </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events (leflunomide)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Of the 2 included studies, <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> had zero events in both groups ‐ absolute and relative risks could not be calculated. In <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>, the ratio of events to total number of participants per group was 1/13 for methotrexate and 2/18 for leflunomide. RR 0.69 (95% CI 0.07 to 6.85). Comments apply to <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> only </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>: absolute risk difference ‐ 3% lower than leflunomide (95% CI 24% lower to 17% higher); risk ratio ‐ 31% lower than leflunomide (95% CI 93% lower to 585% higher). NNTH not calculated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (ciclosporin A)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference and risk ratio could not be calculated due to zero events in both arms. Direction and magnitude of the true effect remain uncertain </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events (ciclosporin A)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000<br/> (58 to 851) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.26<br/> (0.33 to 4.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference ‐ 5% higher than ciclosporin A (95% CI 22% lower to 31% higher); risk ratio ‐ 26% higher than ciclosporin A (95% CI 67% lower to 382% higher). NNTH not calculated </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ACR50: American College of Rheumatology response criteria for 50% improvement; CI: confidence interval; DMARDs: disease‐modifying anti‐rheumatic drugs; HAQ: Health Assessment Questionnaire for Rheumatoid Arthritis; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SAEs: serious adverse events; WAEs: withdrawals due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to risk of bias: judged as unclear or high in at least one domain and at least one study. </p> <p><sup>b</sup>Downgraded twice due to imprecision: low numbers of events with confidence intervals including potentially clinically meaningless benefits. </p> <p><sup>c</sup>Relative changes calculated as absolute change (mean difference) divided by mean at baseline in the placebo group (values were 0.17 on 0 to 3 HAQ). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012722-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-sec-0313">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012722-sec-0030"></div> <section id="CD012722-sec-0031"> <h3 class="title" id="CD012722-sec-0031">Description of the condition</h3> <p>Psoriatic arthritis (PsA) is an inflammatory joint disease affecting approximately 30% of people with psoriasis (<a href="./references#CD012722-bbs2-0072" title="GladmanDD , AntoniC , MeaseP , CleggDO , NashP . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases2005;64(Suppl 2):ii14‐7. [DOI: 10.1136/ard.2004.032482] ">Gladman 2005</a>; <a href="./references#CD012722-bbs2-0096" title="MeasePJ , GladmanDD , PappKA , KhraishiMM , ThaçiD , BehrensF , et al. Prevalence of rheumatologist‐diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology2013;69(5):729‐35. [DOI: 10.1016/j.jaad.2013.07.023] ">Mease 2013</a>; <a href="./references#CD012722-bbs2-0120" title="TruongB , Rich‐GargN , EhstB , DeodharA , KuJ , Vakil‐GilaniK , et al. Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. Clinical, Cosmetic and Investigational Dermatology2015;8:563‐9. [DOI: 10.2147/CCID.S90270] ">Truong 2015</a>). Estimates of the prevalence of PsA in the general population vary between 0.01% and 0.19%, depending on geographical location (<a href="./references#CD012722-bbs2-0116" title="StolwijkC , VanOnnaM , BoonenA , VanTubergenA . The global prevalence of spondyloarthritis: a systematic review and meta‐regression analysis. Arthritis Care and Research2016; Vol. 68, issue 9:1320‐31. [DOI: 10.1002/acr.22831] ">Stolwijk 2016</a>). White people are affected more often than Middle‐Eastern and East‐Asian people (<a href="./references#CD012722-bbs2-0116" title="StolwijkC , VanOnnaM , BoonenA , VanTubergenA . The global prevalence of spondyloarthritis: a systematic review and meta‐regression analysis. Arthritis Care and Research2016; Vol. 68, issue 9:1320‐31. [DOI: 10.1002/acr.22831] ">Stolwijk 2016</a>). Men and women are equally affected across the entire age range, and PsA is more common over 40 years of age among people of both sexes (<a href="./references#CD012722-bbs2-0116" title="StolwijkC , VanOnnaM , BoonenA , VanTubergenA . The global prevalence of spondyloarthritis: a systematic review and meta‐regression analysis. Arthritis Care and Research2016; Vol. 68, issue 9:1320‐31. [DOI: 10.1002/acr.22831] ">Stolwijk 2016</a>). </p> <p>Five distinct patterns of PsA have been described: predominant distal interphalangeal joint involvement, arthritis mutilans, symmetrical polyarthritis, asymmetrical oligoarthritis, and spondyloarthritis (<a href="./references#CD012722-bbs2-0098" title="MollJM , WrightV . Psoriatic arthritis. Seminars in Arthritis and Rheumatism1973;3(1):55‐78. [PUBMED: 4581554] ">Moll 1973</a>). The reported prevalence of each pattern varies, although polyarthritis and oligoarthritis occur most commonly (<a href="./references#CD012722-bbs2-0072" title="GladmanDD , AntoniC , MeaseP , CleggDO , NashP . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases2005;64(Suppl 2):ii14‐7. [DOI: 10.1136/ard.2004.032482] ">Gladman 2005</a>). Overlap of spondyloarthritis and peripheral joint disease occurs in 20% to 40% of people (<a href="./references#CD012722-bbs2-0072" title="GladmanDD , AntoniC , MeaseP , CleggDO , NashP . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases2005;64(Suppl 2):ii14‐7. [DOI: 10.1136/ard.2004.032482] ">Gladman 2005</a>; <a href="./references#CD012722-bbs2-0098" title="MollJM , WrightV . Psoriatic arthritis. Seminars in Arthritis and Rheumatism1973;3(1):55‐78. [PUBMED: 4581554] ">Moll 1973</a>). Periarticular structures may also be involved, leading to enthesitis, tenosynovitis, dactylitis, and fingernail dystrophy (<a href="./references#CD012722-bbs2-0066" title="DuarteGV , FaillaceC , Freire de CarvalhoJ . Psoriatic arthritis. Best Practice and Research Clinical Rheumatology2012;26(1):147‐56. [DOI: 10.1016/j.berh.2012.01.003] ">Duarte 2012</a>; <a href="./references#CD012722-bbs2-0098" title="MollJM , WrightV . Psoriatic arthritis. Seminars in Arthritis and Rheumatism1973;3(1):55‐78. [PUBMED: 4581554] ">Moll 1973</a>). Joint erosions are reported in about 60% of people with PsA (<a href="./references#CD012722-bbs2-0071" title="GladmanDD , ShuckettR , RussellML , ThorneJC , SchachterRK . Psoriatic arthritis (PSA) ‐ an analysis of 220 patients. Quarterly Journal of Medicine1987;62(238):127‐41. [PUBMED: 3659255] ">Gladman 1987</a>; <a href="./references#CD012722-bbs2-0119" title="Torre AlonsoJC , Rodriguez PerezA , Arribas CastrilloJM , Ballina GarciaJ , Riestra NoriegaJL , Lopez LarreaC . Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. British Journal of Rheumatology1991;30(4):245‐50. [DOI: 10.1093/rheumatology/30.4.245] ">Torre Alonso 1991</a>), and approximately 20% develop severe joint destruction and deformity (<a href="./references#CD012722-bbs2-0071" title="GladmanDD , ShuckettR , RussellML , ThorneJC , SchachterRK . Psoriatic arthritis (PSA) ‐ an analysis of 220 patients. Quarterly Journal of Medicine1987;62(238):127‐41. [PUBMED: 3659255] ">Gladman 1987</a>). The diagnosis can be made clinically and is aided by the ‘classification of psoriatic arthritis’ (CASPAR) criteria (<a href="./references#CD012722-bbs2-0056" title="CoatesLC , ConaghanPG , EmeryP , GreenMJ , IbrahimG , MacIverH , et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis and Rheumatism2012;64(10):3150‐5. [DOI: 10.1002/art.34536] ">Coates 2012</a>; <a href="./references#CD012722-bbs2-0117" title="TaylorW , GladmanD , HelliwellP , MarchesoniA , MeaseP , MielantsH . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatism2006;54(8):2665‐73. [DOI: 10.1002/art.21972] ">Taylor 2006</a>). These criteria require the presence of established inflammatory musculoskeletal disease with at least three of the following: a history of psoriasis, dactylitis, psoriatic nail dystrophy, radiographic evidence of juxta‐articular new bone formation, or rheumatoid factor negativity (<a href="./references#CD012722-bbs2-0117" title="TaylorW , GladmanD , HelliwellP , MarchesoniA , MeaseP , MielantsH . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatism2006;54(8):2665‐73. [DOI: 10.1002/art.21972] ">Taylor 2006</a>). </p> <p>Psoriatic arthritis has a negative impact on quality of life, causing pain, joint stiffness, reduced physical function (<a href="./references#CD012722-bbs2-0072" title="GladmanDD , AntoniC , MeaseP , CleggDO , NashP . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases2005;64(Suppl 2):ii14‐7. [DOI: 10.1136/ard.2004.032482] ">Gladman 2005</a>; <a href="./references#CD012722-bbs2-0084" title="HustedJA , GladmanDD , FarewellVT , LongJA , CookRJ . Validating the SF‐36 health survey questionnaire in patients with psoriatic arthritis. Journal of Rheumatology1997;24(3):511‐7. [PUBMED: 9058658] ">Husted 1997</a>; <a href="./references#CD012722-bbs2-0132" title="ZachariaeH , ZachariaeR , BlomqvistK , DavidssonS , MolinL , MørkC , et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Dermato‐Venereologica2002;82(2):108‐13. [DOI: 10.1080/00015550252948130] ">Zachariae 2002</a>), and loss of productivity (<a href="./references#CD012722-bbs2-0125" title="WalshJA , McFaddenML , MorganMD , SawitzkeAD , DuffinKC , KruegerGG , et al. Work productivity loss and fatigue in psoriatic arthritis. Journal of Rheumatology2014;41(8):1670‐4. [DOI: 10.3899/jrheum.140259] ">Walsh 2014</a>). Compared to the general population, people with PsA are at increased risk of cardiovascular disease (incidence rate ratio 1.33, 95% confidence interval (CI) 1.23 to 1.44), as reported in <a href="./references#CD012722-bbs2-0092" title="LiL , HagbergKW , PengM , ShahK , ParisM , JickS . Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis. Journal of Clinical Rheumatology2015;21(8):405‐10. [DOI: 10.1097/RHU.0000000000000306] ">Li 2015</a>, and premature death (standardised mortality ratio 1.36, 95% CI 1.12 to 1.64), as shown by <a href="./references#CD012722-bbs2-0052" title="AliY , TomBD , SchentagCT , FarewellVT , GladmanDD . Improved survival in psoriatic arthritis with calendar time. Arthritis and Rheumatism2007;56(8):2708‐14. [DOI: 10.1002/art.22800] ">Ali 2007</a>. Inflammation is probably a key contributor to these increased risks (<a href="./references#CD012722-bbs2-0122" title="VanDoornumS , McCollG , WicksIP . Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis and Rheumatism2002;46(4):862‐73. [DOI: 10.1002/art.10089] ">Van Doornum 2002</a>), and limited evidence suggests that anti‐inflammatory therapies reduce cardiovascular disease in PsA (<a href="./references#CD012722-bbs2-0104" title="RoubilleC , RicherV , StarninoT , McCourtC , McFarlaneA , FlemingP , et al. The effects of tumour necrosis factor inhibitors, methotrexate, non‐steroidal anti‐inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta‐analysis. Annals of the Rheumatic Diseases2015;74(3):480‐9. [DOI: 10.1136/annrheumdis‐2014‐206624] ">Roubille 2015</a>). Over the last 40 years, the mortality rate in PsA has decreased, possibly as a result of more aggressive treatment of the inflammatory process (<a href="./references#CD012722-bbs2-0052" title="AliY , TomBD , SchentagCT , FarewellVT , GladmanDD . Improved survival in psoriatic arthritis with calendar time. Arthritis and Rheumatism2007;56(8):2708‐14. [DOI: 10.1002/art.22800] ">Ali 2007</a>). </p> </section> <section id="CD012722-sec-0032"> <h3 class="title" id="CD012722-sec-0032">Description of the intervention</h3> <p>Pharmacological management of PsA includes non‐steroidal anti‐inflammatory drugs (NSAIDs), glucocorticoids, and disease‐modifying anti‐rheumatic drugs (DMARDs). Three major classes of DMARDs are available: conventional synthetic DMARDs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs) (<a href="./references#CD012722-bbs2-0113" title="SmolenJS , Van derHeijdeD , MacholdKP , AletahaD , LandewéR . Proposal for a new nomenclature of disease‐modifying antirheumatic drugs. Annals of the Rheumatic Diseases2014;73(1):3‐5. [DOI: 10.1136/annrheumdis‐2013‐204317] ">Smolen 2014a</a>). </p> <p>Methotrexate (MTX) is a csDMARD that can be administered orally, or via subcutaneous or intramuscular injections. It is prescribed weekly, at doses ranging from 5 mg to 25 mg. At this dose and frequency, common side effects include headache, nausea, vomiting, abdominal pain, and mouth ulcers (<a href="./references#CD012722-bbs2-0050" title="AlarcónGS . Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology2000;47(2‐3):259‐71. [DOI: 10.1016/S0162‐3109(00)00184‐3] ">Alarcón 2000</a>). Rare but serious adverse effects include myelosuppression, hepatotoxicity, infection, and pulmonary fibrosis (<a href="./references#CD012722-bbs2-0050" title="AlarcónGS . Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology2000;47(2‐3):259‐71. [DOI: 10.1016/S0162‐3109(00)00184‐3] ">Alarcón 2000</a>). Daily supplementation with folic or folinic acid can alleviate hepatotoxic and gastrointestinal adverse effects (<a href="./references#CD012722-bbs2-0111" title="SheaB , SwindenMV , GhogomuE , OrtizZ , KatchamartW , RaderT , et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD000951.pub2] ">Shea 2013</a>). </p> </section> <section id="CD012722-sec-0033"> <h3 class="title" id="CD012722-sec-0033">How the intervention might work</h3> <p>Methotrexate is used to treat many conditions and may have different effects, depending on the disease and the dose. At high doses used for malignancy, MTX antagonises the folic acid metabolic pathway (<a href="./references#CD012722-bbs2-0062" title="CronsteinBN , ChanES . Treatment of inflammatory disease. In: CronsteinBN , BertinoJR editor(s). Methotrexate. Basel: Birkhauser, 2000:65‐82. ">Cronstein 2000</a>). This disrupts production of nucleotide bases, triggering several cellular processes that culminate in apoptosis (<a href="./references#CD012722-bbs2-0062" title="CronsteinBN , ChanES . Treatment of inflammatory disease. In: CronsteinBN , BertinoJR editor(s). Methotrexate. Basel: Birkhauser, 2000:65‐82. ">Cronstein 2000</a>). At low doses used for inflammatory diseases such as PsA, this pathway does not adequately explain its effects (<a href="./references#CD012722-bbs2-0062" title="CronsteinBN , ChanES . Treatment of inflammatory disease. In: CronsteinBN , BertinoJR editor(s). Methotrexate. Basel: Birkhauser, 2000:65‐82. ">Cronstein 2000</a>). Several alternative mechanisms appear to be important, including accumulation of extracellular adenosine, alteration of the cytokine repertoire of inflammatory cells, and modulation of humoral and cellular immunity (<a href="./references#CD012722-bbs2-0062" title="CronsteinBN , ChanES . Treatment of inflammatory disease. In: CronsteinBN , BertinoJR editor(s). Methotrexate. Basel: Birkhauser, 2000:65‐82. ">Cronstein 2000</a>; <a href="./references#CD012722-bbs2-0064" title="CutoloM , SerioloB , PizzorniC , CraviottoC , SulliA . Methotrexate in psoriatic arthritis. Clinical and Experimental Rheumatology2002;20(6 Suppl 28):S76‐80. [PUBMED: 12463453] ">Cutolo 2002</a>). The biochemical mechanisms that explain these effects remain incompletely understood. </p> <p>Methotrexate is an effective therapy for cutaneous psoriasis (<a href="./references#CD012722-bbs2-0106" title="SchmittJ , RosumeckS , ThomaschewskiG , SporbeckB , HaufeE , NastA . Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials. British Journal of Dermatology2014;170(2):274‐303. [DOI: 10.1111/bjd.12663] ">Schmitt 2014</a>). In rheumatoid arthritis, another inflammatory joint condition, MTX provides effective therapy for improving joint disease and quality of life (<a href="./references#CD012722-bbs2-0093" title="Lopez‐OlivoMA , SiddhanamathaHR , SheaB , TugwellP , WellsGA , Suarez‐AlmazorME . Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD000957.pub2] ">Lopez‐Olivo 2014</a>), and for reducing risk of cardiovascular disease and death (<a href="./references#CD012722-bbs2-0097" title="MichaR , ImamuraF , Wyler von BallmoosM , SolomonDH , HernánMA , RidkerPM , et al. Systematic review and meta‐analysis of methotrexate use and risk of cardiovascular disease. American Journal of Cardiology2011;108(9):1362‐70. [DOI: 10.1016/j.amjcard.2011.06.054] ">Micha 2011</a>; <a href="./references#CD012722-bbs2-0127" title="WaskoMC , DasguptaA , HubertH , FriesJF , WardMM . Propensity‐adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis and Rheumatism2013;65(2):334‐42. [DOI: 10.1002/art.37723] ">Wasko 2013</a>, respectively). Methotrexate has been used historically for PsA on the basis of its benefits in rheumatoid arthritis, and on the assumption that joint pathology is similar to cutaneous pathology in psoriasis. Treating underlying inflammation with DMARDs in PsA aims to achieve improvement in the same clinical outcomes (<a href="./references#CD012722-bbs2-0114" title="SmolenJS , BraunJ , DougadosM , EmeryP , FitzgeraldO , HelliwellP , et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases2014;73(1):6‐16. [DOI: 10.1136/annrheumdis‐2013‐203419] ">Smolen 2014b</a>). </p> </section> <section id="CD012722-sec-0034"> <h3 class="title" id="CD012722-sec-0034">Why it is important to do this review</h3> <p>A systematic review by Jones and colleagues showed a paucity of clinical trials for many csDMARDs for treating PsA, including MTX (<a href="./references#CD012722-bbs2-0085" title="JonesG , CrottyM , BrooksP . Interventions for treating psoriatic arthritis. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD000212] ">Jones 2000</a>). Rheumatoid arthritis and PsA have many fundamental differences, such as the distribution of affected joints, their genetic associations, and their pathophysiological mechanisms (<a href="./references#CD012722-bbs2-0124" title="VealeDJ , FearonU . What makes psoriatic and rheumatoid arthritis so different?. RMD Open2015;1(1):e000025. [DOI: 10.1136/rmdopen‐2014‐000025] ">Veale 2015</a>). Extrapolating results from clinical trials of MTX in the rheumatoid arthritis population to the PsA population is an inadequate method of proving efficacy. Furthermore, evidence indicates that risks of side effects vary between the two populations (<a href="./references#CD012722-bbs2-0060" title="ConwayR , LowC , CoughlanRJ , O'DonnellMJ , CareyJJ . Methotrexate and lung disease in rheumatoid arthritis: a meta‐analysis of randomized controlled trials. Arthritis and Rheumatology2014;66(4):803‐12. [DOI: 10.1002/art.38322] ">Conway 2014</a>; <a href="./references#CD012722-bbs2-0061" title="ConwayR , LowC , CoughlanRJ , O'DonnellMJ , CareyJJ . Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta‐analysis of randomised controlled trials. BMJ2015;350:h1269. [DOI: 10.1136/bmj.h1269] ">Conway 2015</a>; <a href="./references#CD012722-bbs2-0063" title="CurtisJR , BeukelmanT , OnofreiA , CassellS , GreenbergJD , KavanaughA , et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Annals of the Rheumatic Diseases2009;69(1):43‐7. [DOI: 10.1136/ard.2008.101378] ">Curtis 2009</a>). Despite this, MTX is one of the most commonly used therapies worldwide for treatment of PsA (<a href="./references#CD012722-bbs2-0080" title="HelliwellPS , TaylorWJ , CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs ‐ comparison of drugs and adverse reactions. Journal of Rheumatology2008;35(3):472‐6. [PUBMED: 18203324] ">Helliwell 2008</a>; <a href="./references#CD012722-bbs2-0090" title="KvienTK , HeibergMS , LieE , KaufmannC , MikkelsenK , NordvågB‐Y , et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clinical and Experimental Rheumatology2005;23(5 Suppl 39):S188‐94. [PUBMED: 16273806] ">Kvien 2005</a>; <a href="./references#CD012722-bbs2-0118" title="TheanderE , HusmarkT , AleniusG‐M , LarssonPT , TelemanA , GeijerM , et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5‐year follow‐up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Annals of the Rheumatic Diseases2014;73(2):407‐13. [DOI: 10.1136/annrheumdis‐2012‐201972] ">Theander 2014</a>). It is critical that evidence of treatment efficacy and safety be drawn from studies undertaken in a population with the disease of interest. This review is important to further inform clinical decision‐making about the role of methotrexate in treating PsA. </p> <p>We have conducted this review according to the guidelines recommended by the Cochrane Musculoskeletal Group Editorial Board (<a href="./references#CD012722-bbs2-0070" title="GhogomuEA , MaxwellLJ , BuchbinderR , RaderT , Pardo PardoJ , JohnstonRV , et al. Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and metaanalyses. Journal of Rheumatology2014;41(2):194‐205. [DOI: 10.3899/jrheum.121306] ">Ghogomu 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012722-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-sec-0318">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012722-sec-0035"></div> <p>To assess the benefits and harms of methotrexate for psoriatic arthritis in adults.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012722-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-sec-0319">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012722-sec-0036"></div> <section id="CD012722-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012722-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs. We included studies reported as full text, those published as abstract only, and unpublished data. We applied no language restrictions. </p> </section> <section id="CD012722-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included studies of adults aged 18 years or older with a diagnosis of PsA made by a rheumatologist, or by fulfilment of validated classification criteria (e.g. ‘classification of psoriatic arthritis’ (CASPAR) criteria) (<a href="./references#CD012722-bbs2-0117" title="TaylorW , GladmanD , HelliwellP , MarchesoniA , MeaseP , MielantsH . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatism2006;54(8):2665‐73. [DOI: 10.1002/art.21972] ">Taylor 2006</a>). </p> <p>We included studies of participants with conditions other than PsA only if they reported outcomes for participants with PsA as a separate subgroup, or if separate data were available from study authors upon request. </p> </section> <section id="CD012722-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing methotrexate (MTX) at any dose and via any formulation (oral or parenteral) versus placebo, other disease‐modifying anti‐rheumatic drugs (DMARDs) (including bDMARDs), non‐steroidal anti‐inflammatory drugs (NSAIDs), or other analgesics. We allowed co‐intervention with NSAIDs or other analgesics, provided they were used in all treatment arms. </p> </section> <section id="CD012722-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>Major and minor outcomes were informed by the Outcome Measures in Rheumatology 8th Conference core domains for PsA (<a href="./references#CD012722-bbs2-0073" title="GladmanDD , MeasePJ , StrandV , HealyP , HelliwellPS , FitzgeraldO , et al. Consensus on a core set of domains for psoriatic arthritis. Journal of Rheumatology2007;34(5):1167‐70. [0315162X‐34‐1167 [pii]] ">Gladman 2007</a>). The final two minor outcomes were added 'post hoc' to allow meaningful inclusion of studies that preceded the inception of other outcomes. </p> <section id="CD012722-sec-0042"> <h5 class="title">Major outcomes</h5> <p> <ol id="CD012722-list-0001"> <li> <p>Disease response: measured by American College of Rheumatology response criteria for 50% improvement (ACR50) (<a href="./references#CD012722-bbs2-0067" title="FelsonDT , AndersonJJ , BoersM , BombardierC , FurstD , GoldsmithC , et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism1995;38(6):727‐35. [DOI: 10.1002/art.1780380602] ">Felson 1995</a>), Psoriatic Arthritis Response Criteria (PsARC) (<a href="./references#CD012722-bbs2-0055" title="CleggDO , RedaDJ , MejiasE , CannonGW , WeismanMH , TaylorT , et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis and Rheumatism1996;39(12):2013‐20. [DOI: 10.1002/art.1780391210] ">Clegg 1996</a>), or European League Against Rheumatism (EULAR) response criteria (<a href="./references#CD012722-bbs2-0123" title="VanGestelAM , PrevooML , Van't HofMA , VanRijswijkMH , Van dePutteLB , VanRielPL . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis and Rheumatism1996;39(1):34‐40. [DOI: 10.1002/art.1780390105] ">Van Gestel 1996</a>) </p> </li> <li> <p>Function: measured by the Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ) score (<a href="./references#CD012722-bbs2-0069" title="FriesJF , SpitzP , KrainesRG , HolmanHR . Measurement of patient outcome in arthritis. Arthritis and Rheumatism1980;23(2):137‐45. [PUBMED: 7362664] ">Fries 1980</a>), by a modification of the HAQ (<a href="./references#CD012722-bbs2-0100" title="PincusT , SummeyJA , SoraciSA , WallstonKA , HummonNP . Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism1983;26(11):1346‐53. [PUBMED: 6639693] ">Pincus 1983</a>), or by data showing the proportion of participants who achieve a minimally clinically important difference of at least 0.22 (<a href="./references#CD012722-bbs2-0088" title="KosinskiM , ZhaoSZ , DedhiyaS , OsterhausJT , WareJEJr . Determining minimally important changes in generic and disease‐specific health‐related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis and Rheumatism2000;43(7):1478‐87. [PUBMED: 10902749] ">Kosinski 2000</a>) </p> </li> <li> <p>Health‐related quality of life: measured by Short Form‐36 (SF‐36) (<a href="./references#CD012722-bbs2-0126" title="WareJEJr , SherbourneCD . The MOS 36‐item Short‐Form Health Survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. [PUBMED: 1593914] ">Ware 1992</a>), or by a disease‐specific measure such as the Psoriatic Arthritis Quality Of Life (PSORIQOL) assessment tool (<a href="./references#CD012722-bbs2-0094" title="McKennaSP , CookSA , WhalleyD , DowardLC , RichardsHL , GriffithsCE , et al. Development of the PSORIQoL, a psoriasis‐specific measure of quality of life designed for use in clinical practice and trials. British Journal of Dermatology2003;149(2):323‐31. [PUBMED: 12932239] ">McKenna 2003</a>) </p> </li> <li> <p>Disease activity: measured by the Disease Activity Score (28 joints) with erythrocyte sedimentation rate (DAS28‐ESR) (<a href="./references#CD012722-bbs2-0102" title="PrevooML , Van'T HofMA , KuperHH , VanLeeuwenMA , Van DePutteLB , VanRielPL . Modified disease activity scores that include twenty‐eight‐joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism1995;38(1):44‐8. [DOI: 10.1002/art.1780380107] ">Prevoo 1995</a>), by the Clinical Disease Activity Index (CDAI) (<a href="./references#CD012722-bbs2-0051" title="AletahaD , NellVP , StammT , UffmannM , PflugbeilS , MacholdK , et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research and Therapy2005;7(4):R796‐806. [DOI: 10.1186/ar1740] ">Aletaha 2005</a>), or by EULAR response criteria, which include a change in disease activity in addition to activity of the current disease (<a href="./references#CD012722-bbs2-0123" title="VanGestelAM , PrevooML , Van't HofMA , VanRijswijkMH , Van dePutteLB , VanRielPL . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis and Rheumatism1996;39(1):34‐40. [DOI: 10.1002/art.1780390105] ">Van Gestel 1996</a>) </p> </li> <li> <p>Radiographic progression: measured by the Sharp method (<a href="./references#CD012722-bbs2-0110" title="SharpJT , LidskyMD , CollinsLC , MorelandJ . Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism1971;14(6):706‐20. [PUBMED: 5135791] ">Sharp 1971</a>), by the Van der Heijde modification (<a href="./references#CD012722-bbs2-0121" title="Van derHeijdeD . How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology2000;27(1):261‐3. [PUBMED: 10648051] ">Van der Heijde 2000</a>), by the Larsen method (<a href="./references#CD012722-bbs2-0091" title="LarsenA , DaleK , EekM . Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis1977;18(4):481‐91. [PUBMED: 920239] ">Larsen 1977</a>), or by the Psoriatic Arthritis Ratingen Score (PARS) (<a href="./references#CD012722-bbs2-0128" title="WassenbergS , Fischer‐KahleV , HerbornG , RauR . A method to score radiographic change in psoriatic arthritis. Zeitschrift für Rheumatologie2001;60(3):156‐66. [PUBMED: 11475603] ">Wassenberg 2001</a>) </p> </li> <li> <p>Serious adverse events (SAEs) resulting in hospitalisation, disability, or death</p> </li> <li> <p>Withdrawals due to adverse events (WAEs)</p> </li> </ol> </p> </section> <section id="CD012722-sec-0043"> <h5 class="title">Minor outcomes</h5> <p> <ol id="CD012722-list-0002"> <li> <p>Disease response: measured by American College of Rheumatology response criteria for 20% improvement (ACR20) (<a href="./references#CD012722-bbs2-0067" title="FelsonDT , AndersonJJ , BoersM , BombardierC , FurstD , GoldsmithC , et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism1995;38(6):727‐35. [DOI: 10.1002/art.1780380602] ">Felson 1995</a>) </p> </li> <li> <p>Enthesitis: measured by the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) (<a href="./references#CD012722-bbs2-0081" title="Heuft‐DorenboschL , SpoorenbergA , vanTubergenA , LandewéR , vanver TempelH , MielantsH , et al. Assessment of enthesitis in ankylosing spondylitis. Annals of the Rheumatic Diseases2003;62(2):127‐32. [DOI: 10.1136/ard.62.2.127] ">Heuft‐Dorenbosch 2003</a>), or by the Leeds Enthesitis Index (LEI) (<a href="./references#CD012722-bbs2-0078" title="HealyPJ , HelliwellPS . Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Care and Research2008;59(5):686‐91. [DOI: 10.1002/art.23568] ">Healy 2008</a>) </p> </li> <li> <p>Dactylitis: measured by the Leeds Dactylitis Index (LDI) (<a href="./references#CD012722-bbs2-0079" title="HelliwellPS , FirthJ , IbrahimGH , MelsomRD , ShahI , TurnerDeE . Development of an assessment tool for dactylitis in patients with psoriatic arthritis. Journal of Rheumatology2005;32(9):1745‐50. [PUBMED: 16142872] ">Helliwell 2005</a>), or by digit count </p> </li> <li> <p>Pain: measured by the visual analogue scale (VAS) or by the numerical rating scale (NRS) </p> </li> <li> <p>Fatigue: measured by the VAS or the Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale (<a href="./references#CD012722-bbs2-0129" title="WebsterK , CellaD , YostK . The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health and Quality of Life Outcomes2003;1:79. [DOI: 10.1186/1477‐7525‐1‐79] ">Webster 2003</a>), by the Krupp Fatigue Severity Scale (FSS) (<a href="./references#CD012722-bbs2-0089" title="KruppLB , LaRoccaNG , Muir‐NashJ , SteinbergAD . The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology1989;46(10):1121‐3. [PUBMED: 2803071] ">Krupp 1989</a>), or by the Multidimensional Fatigue Inventory (<a href="./references#CD012722-bbs2-0112" title="SmetsEM , GarssenB , BonkeB , DeHaesJC . The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research1995;39(3):315‐25. [PUBMED: 7636775] ">Smets 1995</a>) </p> </li> <li> <p>Skin disease: measured by the Psoriasis Area and Severity Index (PASI) (<a href="./references#CD012722-bbs2-0068" title="FredrikssonT , PetterssonU . Severe psoriasis ‐ oral therapy with a new retinoid. Dermatologica1978;157(4):238‐44. [PUBMED: 357213] ">Fredriksson 1978</a>), or by the proportion with a reduction in PASI of 25%, 50%, or 75% (PASI 25, 50, 75) </p> </li> <li> <p>Total adverse events (AEs)</p> </li> <li> <p>Global assessment of disease activity, as measured by VAS or NRS (<a href="./references#CD012722-bbs2-0109" title="ScottPJ , HuskissonEC . Measurement of functional capacity with visual analogue scales. Rheumatology and Rehabilitation1977;16(4):257‐9. [PUBMED: 414343] ">Scott 1977</a>) </p> </li> <li> <p>Joint count: measured by the total number of tender or swollen joints</p> </li> </ol> </p> <p>We have reported outcomes for time points up to and including six months, and longer than six months. In the 'Summary of findings' tables, we have reported outcomes up to and including six months only. </p> </section> </section> </section> <section id="CD012722-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012722-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Ovid MEDLINE, and Ovid Embase. We searched all databases from their inception to 29 January 2018. </p> <p>We also searched <a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a> and the World Health Organization Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), on 29 January 2018. </p> <p>We set out the search strategies for MEDLINE, Embase, and CENTRAL in <a href="./appendices#CD012722-sec-0297">Appendix 1,</a><a href="./appendices#CD012722-sec-0298">Appendix 2,</a> and <a href="./appendices#CD012722-sec-0299">Appendix 3</a>, respectively, while incorporating a modified search string for RCTs as described by <a href="./references#CD012722-bbs2-0074" title="GlanvilleJM , LefebvreC , MilesJN , Camosso‐StefinovicJ . How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association2006;94(2):130‐6. [PUBMED: 16636704] ">Glanville 2006</a> for MEDLINE, and by <a href="./references#CD012722-bbs2-0131" title="WongSS , WilczynskiNL , HaynesRB . Developing optimal search strategies for detecting clinically sound causation studies in EMBASE. Journal of the Medical Library Association2006;94(1):41‐7. [D030002662 [pii]] ">Wong 2006</a> for Embase. </p> </section> <section id="CD012722-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references; searched relevant manufacturers' websites for trial information; and contacted authors of included studies to learn about additional studies. </p> <p>We searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>), also on 29 January 2018. </p> </section> </section> <section id="CD012722-sec-0047"> <h3 class="title" id="CD012722-sec-0047">Data collection and analysis</h3> <section id="CD012722-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TW, TT) independently screened titles and abstracts of all studies identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. Retrieved studies underwent full‐text review. We identified and recorded reasons for excluding ineligible studies. We resolved disagreements through discussion, or by consultation with a third review author (AM). We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and <a href="./references#CD012722-sec-0311" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD012722-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that was piloted on at least one study in the review to document study characteristics and outcome data. Two review authors (TW, SW) extracted study characteristics from the included studies, and<i>a</i> third review author (AM) spot‐checked study characteristics for accuracy against the trial report. We extracted the following study characteristics. </p> <p> <ol id="CD012722-list-0003"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals, and dates of study. </p> </li> <li> <p>Participants: N, mean age, age range, sex, disease duration, severity of condition, diagnostic criteria, important baseline data, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: drugs used as intervention, concomitant medications, and excluded medications.</p> </li> <li> <p>Comparisons: drug(s) used in non‐intervention arm(s).</p> </li> <li> <p>Outcomes: major and minor outcomes specified and collected, and time points reported.</p> </li> <li> <p>Characteristics of the design of the trial as outlined below in <a href="#CD012722-sec-0050">Assessment of risk of bias in included studies</a>. </p> </li> <li> <p>Notes: funding for the trial and notable declarations of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (TW, SW) independently extracted outcome data from the included studies. We extracted the number of events and the number of participants in each treatment group for dichotomous outcomes, and means and standard deviations and the number of participants in each treatment group for continuous outcomes. We have noted in the <a href="./references#CD012722-sec-0310" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way and when data were transformed or estimated from a graph. We resolved disagreements by reaching consensus or by involving a third person (TT). One review author (TW) transferred data into Review Manager 5 (<a href="./references#CD012722-bbs2-0103" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We double‐checked that data were entered correctly by comparing data presented in the systematic review against the study reports. </p> <p>For numerical data presented only in figures/graphs, we contacted the authors of the report and requested the original data. If necessary, we planned to use plot digitiser software to extract data from graphs or figures. We planned to extract these data in duplicate. </p> <p>When reports included multiple measures of a single outcome, our order of preference was as follows. </p> <p> <ol id="CD012722-list-0004"> <li> <p>For function, we chose the HAQ score, followed by the modified HAQ or the proportion of participants who achieved a minimally clinically important difference of at least 0.22. </p> </li> <li> <p>For disease activity, we chose the DAS28, followed by CDAI or EULAR response criteria.</p> </li> <li> <p>For serious adverse events and withdrawals due to adverse events, we reported the sum total of each. </p> </li> <li> <p>For pain, we preferred a VAS, followed by an NRS.</p> </li> <li> <p>For skin disease, we preferred absolute PASI score, followed by PASI 25, PASI 50, and PASI 75. </p> </li> <li> <p>If both final values and changes from baseline values were reported for the same outcome, we used final values. </p> </li> <li> <p>If both unadjusted and adjusted values for the same outcome were reported, we used unadjusted values. </p> </li> <li> <p>If data were analysed based on an intention‐to‐treat (ITT) sample and another sample (e.g. per‐protocol, as‐treated), we extracted ITT data. </p> </li> </ol> </p> <p>Time points extracted were up to and including six months, and more than six months.</p> </section> <section id="CD012722-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TW, AM) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012722-bbs2-0082" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). We resolved disagreements by discussion or by consultation with another review author (SW). We assessed risk of bias according to the following domains. </p> <p> <ol id="CD012722-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment: this was considered separately for subjective self‐reported outcomes (such as pain and function) and objective outcomes (such as radiographic progression and adverse events). </p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential bias, including differences in baseline characteristics, co‐intervention use, and compliance with study therapy. </p> </li> </ol> </p> <p>We graded each potential source of bias as having high, low, or unclear risk, and we provided a quote from each study report together with a justification for our judgement in the 'Risk of bias' table. We summarised 'Risk of bias' judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be different than for a participant‐reported pain scale). When we judged risk of bias to be no different between outcomes, we reported this as a single domain applicable to all outcomes. We also considered the impact of missing data by examining key outcomes. </p> <p>When information on risk of bias was related to unpublished data or correspondence with a study author, we have noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we have taken into account the risk of bias for studies that contributed to these outcomes. </p> <p>We have presented figures generated by the 'Risk of bias' tool to provide summary assessments of risk of bias. </p> <section id="CD012722-sec-0051"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD012722-bbs2-0130" title="WilsdonTD , WhittleSL , ThynneTR , MangoniAA . Methotrexate for psoriatic arthritis. Cochrane Database of Systematic Reviews2017, Issue 7. [DOI: 10.1002/14651858.CD012722] ">Wilsdon 2017</a>), and we reported any deviations from it under <a href="#CD012722-sec-0307">Differences between protocol and review</a>. </p> </section> </section> <section id="CD012722-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RRs), or as Peto odds ratios (Peto ORs), when the outcome was a rare event (approximately less than 10%), and we used 95% confidence intervals (CIs). We analysed continuous data as mean differences (MDs) or as standardised mean differences (SMDs), also with 95% CIs. We entered data presented as a scale with a consistent direction of effect across studies. </p> <p>When researchers used different scales to measure the same conceptual outcome (e.g. disability), we calculated the SMD, along with a corresponding 95% CI. We back‐translated the SMD to a typical scale (e.g. 0 to 10 for pain) by multiplying the SMD by a typical among‐person standard deviation (SD) (e.g. SD of the control group at baseline from the most representative trial) (<a href="./references#CD012722-bbs2-0107" title="SchünemannH , OxmanAD , VistGE , HigginsJBT , DeeksJJ , GlasziouP , et al. editor(s) . Chapter 12. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.. ">Schünemann 2011a</a>). </p> <p>In the <a href="#CD012722-sec-0079">Effects of interventions</a> section and in the 'Comments' column of the 'Summary of findings' tables, we provided the absolute percentage difference, the relative per cent change from baseline, and the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH). We provided the NNTB or the NNTH only when the outcome showed a statistically significant difference. </p> <p>For dichotomous outcomes, we calculated the NNTB or the NNTH from the control group event rate and the risk ratio, using the Visual Rx NNT calculator (<a href="./references#CD012722-bbs2-0054" title="Dr. Christopher Cates EBM website. www.nntonline.net. Visual Rx. Version 3. Dr. Christopher Cates EBM website. www.nntonline.net, 2008. ">Cates 2008</a>). We produced the NNTB or the NNTH for continuous measures using the Wells calculator, available from the Cochrane Musculoskeletal Editorial Office (<a href="http://musculoskeletal.cochrane.org" target="_blank">musculoskeletal.cochrane.org</a>). </p> <p>For dichotomous outcomes, we calculated the absolute risk difference using the risk difference statistic in Review Manager 5 (<a href="./references#CD012722-bbs2-0103" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and expressed the result as a percentage. For continuous outcomes, we calculated absolute benefit as improvement in the intervention group minus improvement in the control group, in original units, expressed as a percentage. </p> <p>We calculated the relative per cent change for dichotomous data as 'risk ratio ‐ 1' and expressed this as a percentage. For continuous outcomes, we calculated the relative difference in the change from baseline as absolute benefit divided by baseline mean of the control group, expressed as a percentage. </p> </section> <section id="CD012722-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>When a single trial reported multiple trial arms, we included only relevant arms.</p> </section> <section id="CD012722-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when we identified a study as abstract only, when data were not available for all participants). When this was not possible, and when we thought that missing data might introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing a sensitivity analysis<b>.</b> We clearly described any assumptions and imputations for handling missing data, and we explored the effect of imputation by performing sensitivity analyses. </p> <p>For dichotomous outcomes (e.g. number of withdrawals due to adverse events), we calculated the event rate using the number of participants randomised in the group as the denominator. </p> <p>For continuous outcomes (e.g. mean change in pain score), we calculated MD or SMD based on the number of participants analysed at that time point. If study authors did not present the number of participants analysed for each time point, we used the number of randomised participants in each group at baseline. </p> <p>When possible, we computed missing standard deviations from other statistics such as standard errors, confidence intervals, or P values, according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012722-bbs2-0083" title="HigginsJPT , DeeksJJ , editor(s) . Chapter 7. Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011b</a>). If we could not calculate standard deviations, we planned to impute them (e.g. from other studies in the meta‐analysis). </p> </section> <section id="CD012722-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological diversity in terms of participants, interventions, outcomes, and study characteristics of the included studies, to determine whether meta‐analysis was appropriate. We assessed statistical heterogeneity by visually inspecting the forest plot to look for obvious differences in results between studies and by using I² and Chi² statistical tests. </p> <p>As recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012722-bbs2-0065" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9. Analysing data and undertaking meta‐analyses. In Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from handbook.cochrane.org. ">Deeks 2011</a>), we interpreted I² values as follows: 0% to 40% 'might not be important'; 30% to 60% may represent 'moderate' heterogeneity; 50% to 90% may represent 'substantial' heterogeneity; and 75% to 100% represents 'considerable' heterogeneity. We have considered that the importance of I² depends on the magnitude and direction of effects and on the strength of evidence for heterogeneity. </p> <p>We interpreted the Chi² test such that a P value of 0.10 or less indicates evidence of statistical heterogeneity. </p> <p>When identified, we reported substantial heterogeneity and investigated possible causes by following the recommendations provided in Section 9.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> <section id="CD012722-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>We created and examined a funnel plot to explore possible small‐study biases. In interpreting funnel plots, we examined different possible reasons for funnel plot asymmetry and related this information to review results. If we were able to pool more than 10 trials, we planned to undertake formal statistical tests to investigate funnel plot asymmetry, and to follow the recommendations provided in Section 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012722-bbs2-0115" title="SterneJAC , EggerM , MoherD , editor(s) . Chapter 10. Addressing reporting biases. In Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Sterne 2011</a>). </p> <p>To assess bias in outcome reporting, we checked trial protocols (if available) against published reports. For studies published after 1 July 2005, we screened the Clinical Trial Register at the International Clinical Trials Registry Platform of the World Health Organization (<a href="http://apps.who.int/trialssearch" target="_blank">apps.who.int/trialssearch</a>) for the a priori trial protocol. We evaluated whether selective reporting of outcomes was evident. </p> </section> <section id="CD012722-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only when this was meaningful (e.g. when treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). We arranged data according to comparator (i.e. placebo or other DMARD) and duration of follow‐up (i.e. up to six months or beyond six months). </p> <p>We planned to use a random‐effects model and to perform a sensitivity analysis using a fixed‐effect model. </p> <section id="CD012722-sec-0058"> <h5 class="title">GRADE and 'Summary of findings' tables</h5> <p>We created 'Summary of findings' (SoF) tables using the following outcomes.</p> <p> <ol id="CD012722-list-0006"> <li> <p>Disease response.</p> </li> <li> <p>Function.</p> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Disease activity.</p> </li> <li> <p>Radiographic progression.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> </ol> </p> <p>The comparator in the first SoF table is placebo. The second SoF table shows comparisons of other DMARDs (including bDMARDs). </p> <p>Two review authors (TW, SW) independently assessed the quality of the evidence. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to studies that contributed data to the meta‐analyses for the prespecified outcomes, and we reported the quality of evidence as high, moderate, low, or very low. We used methods and recommendations described in Sections 8.5 and 8.7 and in Chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012722-bbs2-0082" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012722-bbs2-0107" title="SchünemannH , OxmanAD , VistGE , HigginsJBT , DeeksJJ , GlasziouP , et al. editor(s) . Chapter 12. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.. ">Schünemann 2011a</a>; <a href="./references#CD012722-bbs2-0108" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH , editor(s) . Chapter 11. Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Schünemann 2011b</a>). We planned to use GRADEpro GDT software to prepare the SoF tables (<a href="./references#CD012722-bbs2-0076" title="McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Development Tool. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015. ">GRADEpro GDT 2015</a>). We planned to justify all decisions to downgrade or upgrade the quality of studies by using footnotes and by providing comments to aid the reader's understanding of the review when necessary. We planned to provide the NNTB based on absolute and relative per cent changes in the 'Comments' column of the SoF tables, as described above (see <a href="#CD012722-sec-0052">Measures of treatment effect</a>). </p> </section> </section> <section id="CD012722-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD012722-list-0007"> <li> <p>Oral versus parenteral routes of administration.</p> </li> <li> <p>Lower dose (15 mg or less) versus higher dose (greater than 15 mg).</p> </li> <li> <p>Peripheral arthritis (symmetrical polyarthritis, oligoarthritis, distal interphalangeal arthritis, arthritis mutilans) versus axial arthritis (spondyloarthritis). </p> </li> </ol> </p> <p>Methotrexate has variable absorption when administered orally at doses above 15 mg (<a href="./references#CD012722-bbs2-0077" title="HamiltonRA , KremerJM . Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. British Journal of Rheumatology1997;36(1):86‐90. [PUBMED: 9117183] ">Hamilton 1997</a>). Parenteral administration is predictable and linear throughout the dose range (<a href="./references#CD012722-bbs2-0077" title="HamiltonRA , KremerJM . Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. British Journal of Rheumatology1997;36(1):86‐90. [PUBMED: 9117183] ">Hamilton 1997</a>; <a href="./references#CD012722-bbs2-0105" title="SchiffMH , JaffeJS , FreundlichB . Head‐to‐head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug‐exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Annals of the Rheumatic Diseases2014;73(8):1549‐51. [DOI: 10.1136/annrheumdis‐2014‐205228] ">Schiff 2014</a>), hence effectiveness may differ between these subgroups. </p> <p>Variation in treatment response by pattern of arthritis might highlight an area for further investigation. </p> <p>We planned to use the following outcomes in subgroup analyses for all comparisons.</p> <p> <ol id="CD012722-list-0008"> <li> <p>Measure of disease activity/response (ACR, DAS28, PsARC).</p> </li> <li> <p>Assessment of function (HAQ).</p> </li> <li> <p>Reported serious adverse events and withdrawals due to adverse events.</p> </li> </ol> </p> <p>We planned to use the formal test for subgroup interactions provided in Review Manager 5 (<a href="./references#CD012722-bbs2-0103" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and to use caution in interpreting subgroup analyses, as advised in Section 9.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012722-bbs2-0065" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9. Analysing data and undertaking meta‐analyses. In Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from handbook.cochrane.org. ">Deeks 2011</a>). We planned to compare the magnitude of effects between subgroups by assessing overlap of the confidence intervals of summary estimates. Non‐overlap of confidence intervals indicates statistical significance. </p> <p>We were unable to extract these data from the included studies, and so we could not complete these subgroup analyses. </p> </section> <section id="CD012722-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>When we had identified sufficient studies, we planned to perform sensitivity analyses to assess the impact of any bias attributable to inadequate or unclear treatment allocation, including studies with quasi‐randomised designs (selection bias), blinding of participant/assessor (detection bias), and loss to follow‐up (attrition bias) compared to studies without these limitations (low risk vs high risk or unclear risk). We planned to apply this approach to the major outcomes and to both comparisons. We found insufficient studies and were unable to complete these sensitivity analyses. </p> <p>We explored the effect that imputed values had on outcomes for all studies when this information was available. Data to perform this sensitivity analysis were available for only one study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>), for which we examined disease response (PsARC, ACR20), function, disease activity, pain, skin disease, patient and physician global assessments of disease activity, and swollen and tender joint counts. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012722-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012722-sec-0061"></div> <section id="CD012722-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD012722-sec-0063"> <h4 class="title">Results of the search</h4> <p>We identified 6668 records through database searches and two additional records from other sources. After removing duplicates, we screened 4245 records by abstract and title and excluded 4197 records. We retrieved the full‐text publications for 48 records, and we included eight records in this review (<a href="#CD012722-fig-0001">Figure 1</a>). We did not identify any studies available as unpublished data only. </p> <div class="figure" id="CD012722-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012722-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012722-sec-0064"> <h4 class="title">Included studies</h4> <p>Details of individual included trials can be viewed in the <a href="./references#CD012722-sec-0310" title="">Characteristics of included studies</a> table. We had two studies ‐ <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>, published in Russian, and <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>, published in Mandarin ‐ translated to English. We identified four records as relating to a single RCT and collated them as a single study record at the start of the full‐text review phase (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). </p> <section id="CD012722-sec-0065"> <h5 class="title">Design</h5> <p>We included eight RCTs (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). One study used a cross‐over design (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>), and the other seven studies described a parallel design. </p> </section> <section id="CD012722-sec-0066"> <h5 class="title">Sample size</h5> <p>The largest trial included 221 participants (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>), and the smallest 21 participants (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>). Only one trial was registered with a clinical trial registry (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). </p> </section> <section id="CD012722-sec-0067"> <h5 class="title">Setting</h5> <p>All studies were conducted in an outpatient setting in Italy, the United Kingdom, the United States of America, China, Russia, or Bangladesh. </p> </section> <section id="CD012722-sec-0068"> <h5 class="title">Participants</h5> <p>All studies included adults with psoriatic arthritis recruited from rheumatology clinics. One study enrolled participants from 16 years of age (<a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>); however, screening review authors (TW, TT) agreed to include it, as no participants were younger than 30 years of age. No studies used the CASPAR criteria for psoriatic arthritis (PsA) classification. Although no study explicitly stated that the diagnosis of PsA was made by a rheumatologist, all studies either recruited participants from rheumatology clinics, or ensured that a rheumatologist was involved in the study. </p> </section> <section id="CD012722-sec-0069"> <h5 class="title">Interventions</h5> <p>Five studies compared methotrexate versus placebo (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). Four studies compared methotrexate versus other DMARDs (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>), and two of these were multi‐arm trials. One study compared methotrexate versus NSAIDs (we considered this as a placebo arm because NSAIDs were permitted in all intervention groups), parenteral gold, and sulfasalazine (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>). One study compared methotrexate monotherapy versus leflunomide monotherapy and both therapies combined (<a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). Of the remaining two trials with a DMARD comparator, one compared methotrexate versus leflunomide (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>), and another compared methotrexate versus ciclosporin (<a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>). </p> <p>Doses of oral methotrexate used across studies varied from 7.5 mg to 25 mg weekly. Although this dose range is considered standard, we considered doses greater than 15 mg as 'higher‐dose'. It was not possible to determine how many participants received methotrexate doses greater than 15 mg. Two studies used parenteral methotrexate, at doses of 10 mg weekly in <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> and 1 mg/kg to 3 mg/kg every 10 days in <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>. Doses of other DMARDs included leflunomide 20 mg daily in <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> and <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>, and elemental gold equivalent 34 mg and sulfasalazine 1 g twice a day in <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>. </p> <p>Use of concomitant analgesia was permitted in all trials, and these agents varied from NSAIDs to oral, parenteral, or intra‐articular corticosteroids. </p> </section> <section id="CD012722-sec-0070"> <h5 class="title">Outcomes</h5> <p>Seven studies reported outcomes for time points up to six months (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>), and two studies reported outcomes for time points beyond six months (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>). All studies did not report all outcomes. Three studies did not report outcomes in an extractable way (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>), and study authors either could not be contacted or were unable to provide additional information upon request. <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> provided additional information for ITT and complete case cohorts via written correspondence. <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> was unable to provide additional information. The authors of three studies did not respond to requests for additional information (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). </p> <p>Our original protocol specified that we would extract outcomes for quality of life, radiographic progression, enthesitis, dactylitis, and fatigue (<a href="./references#CD012722-bbs2-0130" title="WilsdonTD , WhittleSL , ThynneTR , MangoniAA . Methotrexate for psoriatic arthritis. Cochrane Database of Systematic Reviews2017, Issue 7. [DOI: 10.1002/14651858.CD012722] ">Wilsdon 2017</a>). No studies reported these outcomes; however, we observed that studies consistently reported tender and swollen joint counts and patient and physician global assessments of disease activity. The most recent Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) recommendations acknowledge these outcomes as having clinical significance (<a href="./references#CD012722-bbs2-0099" title="OrbaiA‐M , deWitM , MeasePJ , DuffinKC , ElmamounM , TillettW , et al. Updating the Psoriatic Arthritis (PsA) Core Domain Set: a report from the PsA Workshop at OMERACT 2016. Journal of Rheumatology2017;44:1522‐8. [DOI: 10.3899/jrheum.160904] ">Orbai 2017</a>). Further, these findings directly assisted in answering the primary question of this review, and so we extracted data for these outcomes and included them. </p> </section> </section> <section id="CD012722-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded 40 studies after reviewing the full‐text records. We excluded studies because they used the wrong study design (eight studies; <a href="./references#CD012722-bbs2-0009" title="Abu‐ShakraM , GladmanDD , ThorneJC , LongJ , GoughG , FarewellVT . Long term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. Journal of Rheumatology1995;22:241‐5. ">Abu‐Shakra 1995</a>; <a href="./references#CD012722-bbs2-0013" title="CalguneriM , CobankaraV , OzturkMA , ErtenliI , KirazS , AprasS . Combination therapies in spondyloarthropathies. Kobe Journal of Medical Science2004;50(2):31‐7. ">Calguneri 2004</a>; <a href="./references#CD012722-bbs2-0021" title="CombeB , KerkmannU , BrockF , GalloG . Response to etanercept with or without methotrexate combination therapy in patients with psoriatic arthritis. Arthritis and Rheumatism2013;65:S154. ">Combe 2013</a>; <a href="./references#CD012722-bbs2-0022" title="CombeB , BehrensF , McHughN , BrockF , KerkmannU , KolaB , et al. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. Journal of Rheumatology2016;43(6):1063‐7. ">Combe 2016</a>; <a href="./references#CD012722-bbs2-0024" title="FeldgesDH , BarnesCG . Treatment of psoriatic arthropathy with either azathioprine or methotrexate. Rheumatology and Rehabilitation1974;13(3):120‐4. ">Feldges 1974</a>; <a href="./references#CD012722-bbs2-0029" title="GoupilleP , ValatJP , GladmanDD . Is methotrexate really effective in patients with psoriatic arthritis?. Journal of Rheumatology1995;22(12):2369‐70. ">Goupille 1995</a>; <a href="./references#CD012722-bbs2-0036" title="MazzantiG , ColonoL , deSabbataG , PaladiniG . Methotrexate and cyclosporine combined therapy in severe psoriatic arthritis. A pilot study. Acta Dermato‐Venerologica (Stockholm)1994;186:116‐7. ">Mazzanti 1994</a>; <a href="./references#CD012722-bbs2-0040" title="MerolaJ , SundaramM , YangM , LiJ , GalebachP , OkunM . Adalimumab is associated with reduced risk of joint‐related signs and symptoms compared with methotrexate in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology2016;1:AB235. ">Merola 2016</a>), the wrong intervention (13 studies; <a href="./references#CD012722-bbs2-0010" title="AtzeniF , BoccassiniL , AnitvalleM , SalaffiF , Sarzi‐PuttiniP . Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Annals of Rheumatic Diseases2011;70(4):712‐4. ">Atzeni 2011</a>; <a href="./references#CD012722-bbs2-0020" title="CollinsA , van derHeijdeD , LandeweR , MeaseP , McInnesI , ConaghanP , et al. Secukinumab, a monoclonal antibody to interleukin‐17a, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double‐blind, placebo‐controlled study. Internal Medicine Journal2015;45(Suppl 2):42. ">Collins 2015</a>; <a href="./references#CD012722-bbs2-0023" title="ContiF , CeccarelliF , PrioriR , IagnoccoA , SignoreA , VelsiniG . Intra‐articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic antitumour necrosis factor alpha. Annals of Rheumatic Diseases2008;67:1787‐90. ">Conti 2008</a>; <a href="./references#CD012722-bbs2-0027" title="GottliebAB , McInnesI , MeaseP , MpofuS . Secukinumab improves signs and symptoms of psoriatic arthritis: results of phase 3 FUTURE 2 study stratified by concomitant methotrexate use. Journal of the American Academy of Dermatology2016;1:AB270. ">Gottlieb 2016a</a>; <a href="./references#CD012722-bbs2-0028" title="GottliebA , MeaseP , McInnesI , MpofuS . Secukinumab inhibits radiographic progression in patients with psoriatic arthritis: results of phase 3 FUTURE 1 study stratified by concomitant methotrexate use. Journal of the American Academy of Dermatology2016;1:AB271. ">Gottlieb 2016b</a>; <a href="./references#CD012722-bbs2-0034" title="KavanaughA , GladmanD , BeutlerA , HanC , ChandranV . Golimumab treatment inhibits progression in joint damage in patients with psoriatic arthritis regardless of baseline disease severity. Journal of Rheumatology2012;39:1736‐7. ">Kavanaugh 2012</a>; <a href="./references#CD012722-bbs2-0035" title="KhraishiM , GottliebAB , HoepkenB , PetersonL , MeasePJ . The effect of certolizumab pegol on skin manifestations of psoriatic arthritis over 4 years of treatment. Arthritis and Rheumatology2016;68(Suppl 10):1724. ">Khraishi 2016</a>; <a href="./references#CD012722-bbs2-0037" title="McInnesIB , MeasePJ , KirkhamB , KavanaughA , RitchlinCT , RahmanP , et al. Secukinumab, a human anti‐interleukin 17a monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet2015;386(9999):1137‐46. ">McInnes 2015</a>; <a href="./references#CD012722-bbs2-0038" title="MeaseP , GottliebAB , BermanA , DrescherE , XingJ , BanerjeeJ , et al. A phase IIb, randomized, double‐blind, placebo‐controlled, dose‐ranging, multicenter study to evaluate the efficacy and safety of clazakinumab, an anti‐IL‐6 monoclonal antibody, in adults with active psoriatic arthritis. Arthritis and Rheumatology2015;66:S423. ">Mease 2015</a>; <a href="./references#CD012722-bbs2-0041" title="MinT . Observation of efficacy of biological combined with different DMARDs against psoriatic arthritis. International Journal of Rheumatic Diseases2016;19:163. ">Min 2016</a>; <a href="./references#CD012722-bbs2-0046" title="SchettGA , HuA , StevensR . Oral apremilast is effective with and without concomitant methotrexate therapy in the treatment of subjects with active psoriatic arthritis. Arthritis and Rheumatism2011;63(Suppl 10):780. ">Schett 2011</a>; <a href="./references#CD012722-bbs2-0047" title="SchettG , HuA , StevensR . Oral apremilast is effective in the treatment of subjects with active psoriatic arthritis with and without concomitant methotrexate therapy. Zeithschrift fur Rheumatologie2012;71:136. ">Schett 2012</a>; <a href="./references#CD012722-bbs2-0048" title="SzentpeteryA , HeffernanEJ , HaroonM , GallagherP , BakerA‐M , CooneyM , et al. Abatacept improves synovitis as assessed by magnetic resonance imaging (MRI) in psoriatic arthritis ‐ preliminary analysis from a single centre, placebo‐controlled, crossover study. Arthritis and Rheumatology2015;66:S607. ">Szentpetery 2014</a>), the wrong comparator (11 studies; <a href="./references#CD012722-bbs2-0011" title="BaranauskaiteA , RaffayovaH , KungurovNV , KubanovaA , VenalisA , HelmleL , et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate‐naive patients: the RESPOND study. Annals of Rheumatic Diseases2012;71:541‐8. ">Baranauskaite 2012</a>; <a href="./references#CD012722-bbs2-0014" title="CoatesLC , MoverleyAR , McParlandL , BrownS , CollierH , LawJ , et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthitis and Rheumatism2013;65:S346. ">Coates 2013</a>; <a href="./references#CD012722-bbs2-0015" title="CoatesL , MoverleyA , McParlandL , BrownS , CollierH , BrownSR , et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open‐label, randomised controlled trial. Lancet2014;383:S36. ">Coates 2014</a>; <a href="./references#CD012722-bbs2-0016" title="CoatesLC , HelliwellPS . Methotrexate in early psoriatic arthritis ‐ open label data from the TICOPA study. Annals of Rheumatic Diseases2015;74:861. ">Coates 2015a</a>; <a href="./references#CD012722-bbs2-0017" title="CoatesLC , MoverleyAR , McParlandL , BrownS , Navarro‐CoyN , O'DwyerJL , et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open‐label, randomised, controlled trial. Lancet2015;386(10012):2489‐98. ">Coates 2015b</a>; <a href="./references#CD012722-bbs2-0018" title="CoatesLC , HelliwellPS . Methotrexate in the tight control in psoriatic arthritis study. Journal of Rheumatology2016;43(2):356‐61. ">Coates 2016a</a>; <a href="./references#CD012722-bbs2-0019" title="CoatesLC , MahmoodF , EmeryP , ConaghanPG , HelliwellPS . The dynamics of response as measured by multiple composite outcome tools in the tight control of inflammation in early psoriatic arthritis (TICOPA) trial. Annals of Rheumatic Diseases2017;76(10):1688‐92. ">Coates 2017</a>; <a href="./references#CD012722-bbs2-0031" title="IschenkoA , KleymenovaI , RaymuevK , SolovievaL , AntipovaT , SimbirtsevA . Comparison study of recombinant human interleukin‐1 receptor antagonist for treating psoriatic and rheumatoid arthritis. Cytokine2010;52:22. [DOI: 10.1016/j.cyto.2010.07.095] ">Ischenko 2010</a>; <a href="./references#CD012722-bbs2-0042" title="O'BrienWM , VanScottEJ , BlackRL , EizenAZ , BunimJJ . Clinical trial of amethopterin (methotrexate) in psoriatic and rheumatoid arthritis (preliminary report). Arthritis and Rheumatism1962;5(3):312. ">O'Brien 1962</a>; <a href="./references#CD012722-bbs2-0043" title="RaffayovaH , KungurovN , KubanovaA , BaranauskaiteA , VenalisA , HelmleL , et al. Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: the RESPOND trial. Arthritis and Rheumatism2009;60:1780. ">Raffayova 2009a</a>; <a href="./references#CD012722-bbs2-0044" title="RaffayovaH , KunvurovN , KubanovaA , BaranauskaiteA , VenalisA , HelmleL , et al. Infliximab plus methotrexate significantly improves synovitis and psoriatic lesions in methotrexate naive psoriatic arthritis (PsA) patients: results of the RESPOND trial. Arthritis and Rheumatism2009;60:1256. ">Raffayova 2009b</a>), or the wrong patient population (six studies; <a href="./references#CD012722-bbs2-0025" title="FraserAD , vanKuijkAW , WesthovensR , KarimZ , WakefieldR , GerardsAH , et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Annals of Rheumatic Diseases2005;64(6):859‐64. ">Fraser 2005</a>; <a href="./references#CD012722-bbs2-0026" title="GlinatsiD , BirdP , GandjbakhchF , MeasePJ , BoyesenP , PeterfyCH , et al. Validation of the OMERACT psoriatic arthritis magnetic resonance imaging score (PsAMRIS) for the hand and foot in a randomized placebo‐controlled trial. Journal of Rheumatology2015;42(12):2473‐9. ">Glinatsi 2015</a>; <a href="./references#CD012722-bbs2-0032" title="KavanaughA , AntoniCE , GladmanDD . The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Annals of Rheumatic Diseases2006;65(8):1038‐43. ">Kavanaugh 2006a</a>; <a href="./references#CD012722-bbs2-0033" title="KavanaughA , AntoniC , KruegerGG , YanS , BalaM , DooleyLT , et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Annals of Rheumatic Diseases2006;65:471‐7. ">Kavanaugh 2006b</a>; <a href="./references#CD012722-bbs2-0039" title="MeaseP , GottliebAB , van derHeijdeD , FitzGeraldO , JohnsenA , NysM , et al. Abatacept in the treatment of active psoriatic arthritis: 24‐week results from a phase III study. Arthritis and Rheumatology2016;68(Suppl 10):1366‐9. ">Mease 2016</a>; <a href="./references#CD012722-bbs2-0045" title="SaurahJH , UnnebrinkK , GoldblumO , BissonnetteR . Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Journal of the American Academy of Dermatology2010;1:AB124. ">Saurat 2010</a>), or because we were unable to extract data specific to PsA participants (two studies; <a href="./references#CD012722-bbs2-0012" title="BirdHA , RingEF , DanielR , BaconPA . Comparison of intra‐articular methotrexate with intra‐articular triamcinolone hexacetonide by thermography. Current Medical Research and Opinion1977;5(2):141‐6. ">Bird 1977</a>; <a href="./references#CD012722-bbs2-0030" title="HallGH , JonesBJ , HeadAC , JonesVE . Intra‐articular methotrexate. Clinical and laboratory study in rheumatoid and psoriatic arthritis. Annals of Rheumatic Diseases1978;37(4):351‐6. ">Hall 1978</a>). The excluded studies can be matched to their respective reasons in the <a href="./references#CD012722-sec-0311" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012722-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>One study is currently in progress and is due for completion of data collection in 2018 (<a href="./references#CD012722-bbs2-0049" title="A multicenter, double‐blind, randomized controlled study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis. Ongoing study 3 March 2015. ">NCT02376790</a>). The corresponding entry at ClinicalTrials.gov describes a multi‐armed RCT comparing etanercept monotherapy, methotrexate monotherapy, and the combination of both therapies for psoriatic arthritis. The monotherapy arms might be suitable for inclusion in future versions of this review. </p> </section> </section> </section> <section id="CD012722-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for included studies can be viewed as a summary table (<a href="#CD012722-fig-0002">Figure 2</a>) or graph (<a href="#CD012722-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012722-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012722-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012722-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012722-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012722-sec-0074"> <h4 class="title">Allocation</h4> <p>Although all studies were described as randomised, only two studies adequately described their randomisation process (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; low risk of bias). Only a single study adequately described allocation concealment methods (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; low risk of bias). We judged all other studies to be at unclear or high risk of bias because they poorly described their method, or because we believed their method was likely to introduce bias. </p> </section> <section id="CD012722-sec-0075"> <h4 class="title">Blinding</h4> <p>We judged only one study to be at low risk of bias for blinding, as the description of blinding methods was adequate (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). Two studies were of an open‐label design (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; high risk of performance and detection bias). One study was of a double‐blind design but did not describe blinding methods in any detail (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; uncertain risk of performance and detection bias). <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a> used a placebo tablet but did not provide further detail regarding blinding methods (uncertain risk of bias). <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> did not use placebo tablets and did not describe blinding methods in any detail; we judged this study to be at high risk of performance bias and uncertain risk of detection bias. The remaining studies did not report any blinding methods in any detail (<a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>; high risk of bias). </p> </section> <section id="CD012722-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>Only one study described a method of handling missing data (via multiple imputation) that may have influenced our interpretation of study results in favour of methotrexate (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; unclear risk of attrition bias). One study had a low attrition rate that we judged unlikely to alter our interpretation of the results, which we deemed as having low risk of bias (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>). The remaining studies did not describe handling of missing data, although attrition was low in three studies (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>; unclear risk of attrition bias), and was high in three studies (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>; high risk of attrition bias). </p> </section> <section id="CD012722-sec-0077"> <h4 class="title">Selective reporting</h4> <p>Only one trial was registered in a clinical trial registry and showed selective reporting of complete case analysis data but not of ITT analysis data (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). Also these investigators collected but did not report quality of life data; we judged this study to be at high risk of reporting bias (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). No other included study had a published trial protocol nor clinical trial registration. Due to our inability to substantiate that reporting bias had not occurred, we judged the remaining seven studies to be at unclear risk of reporting bias (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). </p> </section> <section id="CD012722-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>We considered the similarity of baseline characteristics, use of co‐interventions, and compliance as a combined other potential source of bias. We judged only one study to be at low risk of bias (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>), and we determined that all other trials were at unclear risk of bias due to differences between treatment groups in each of these domains. </p> </section> </section> <section id="CD012722-sec-0079"> <h3 class="title" id="CD012722-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD012722-tbl-0001"><b>Summary of findings for the main comparison</b> Methotrexate compared to placebo for psoriatic arthritis (up to six months)</a>; <a href="./full#CD012722-tbl-0002"><b>Summary of findings 2</b> Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)</a> </p> <p>Results for the major outcomes can be reviewed in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>. The remaining results can be viewed in <a href="./references#CD012722-sec-0295" title="">Data and analyses</a>. We planned subgroup analyses for oral versus parenteral methotrexate, lower‐dose versus higher‐dose methotrexate, and peripheral versus axial disease. The included studies did not provide data to enable performance of these analyses. We have grouped results for methotrexate versus other disease‐modifying anti‐rheumatic drugs (DMARDs) according to the DMARD comparator. </p> <section id="CD012722-sec-0080"> <h4 class="title">Methotrexate versus placebo (up to six months)</h4> <p>Four studies with a placebo comparator reported outcomes up to six months (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). Not all studies reported all outcomes. One study used a cross‐over design, and we planned to extract data from the first phase of the study for comparison of methotrexate versus placebo (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>). Outcomes reported were not extractable for use in this review, and study authors could not be reached. Another study reported adverse events but reported other outcomes of interest as median change from baseline without any measure of dispersion (<a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). Study authors were unable to provide additional information. Only adverse event data were extractable. <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> reported several outcomes of interest but presented data as medians with an interquartile range. We assumed the data were skewed, and study authors did not respond to our requests for clarification. We did not estimate means and SD from these values. For this reason, and because the risk of bias was unclear or high across most domains, we did not pool data from <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> with those from <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> for most outcomes. </p> <section id="CD012722-sec-0081"> <h5 class="title">Major outcomes (comparison 1)</h5> <section id="CD012722-sec-0082"> <h6 class="title">Disease response (psoriatic arthritis response criteria (PsARC))</h6> <p>Only one study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) reported data for this outcome. Study authors responded to requests for unpublished data on disease response for the intention‐to‐treat (ITT) cohort (n = 221), which included imputed values for missing data. To communicate uncertainty in the result, they provided a mean and a standard error. They did not provide absolute numbers of Psoriatic Arthritis Response Criteria (PsARC) responders from the ITT cohort but provided them for the complete case cohort. PsARC response is a dichotomous outcome (i.e. responder, non‐responder); therefore we used complete case PsARC responders at six months and assumed that all other participants from the ITT cohort were non‐responders. For methotrexate, 41 of 109 achieved PsARC response, and for placebo, 24 of 112 achieved PsARC response. We calculated a risk ratio (RR) for achieving PsARC response with methotrexate of 1.76 (95% confidence interval (CI) 1.14 to 2.70; <a href="./references#CD012722-fig-0004" title="">Analysis 1.1</a>), an absolute risk difference of 0.16 (95% CI 0.04 to 0.28), and a number needed to treat for an additional beneficial outcome (NNTB) of 6 (95% CI 4 to 25). </p> <p>We performed a sensitivity analysis using data from the complete case cohort only. Study authors provided unpublished data on the number of PsARC responders in the complete case cohort (N = 128) at six months. For methotrexate, 41 of 67 achieved PsARC response, and for placebo, 24 of 61 achieved PsARC response. We calculated a risk ratio for achieving a PsARC response with methotrexate of 1.56 (95% CI 1.08 to 2.24; <a href="./references#CD012722-fig-0039" title="">Analysis 9.1</a>), an absolute risk difference of 0.22 (95% 0.05 to 0.39), and an NNTB of 5 (95% CI 3 to 20). </p> <p>In the published manuscript for <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>, study authors used the imputed values and calculated an increased odds ratio (OR) of PsARC response for methotrexate (OR 1.77, 95% CI 0.97 to 3.23). This was a statistically non‐significant result (P = 0.06). </p> <p>We have included results from our ITT analysis in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>. We judged evidence quality to be low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0083"> <h6 class="title">Function</h6> <p>Only one study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) reported data for this outcome. We extracted data for the ITT cohort (n = 221), including imputed values for missing data. We estimated the standard deviation (SD) from the 95% CI in the published manuscript. At six months, mean function (Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ), scale 0 to 3; higher scores indicate greater disability) in the placebo group was 1 point. We calculated a mean difference (MD) in HAQ scores of ‐0.30 (95% CI ‐0.51 to ‐0.09; <a href="./references#CD012722-fig-0005" title="">Analysis 1.2</a>). The negative sign indicates a lower HAQ score for methotrexate. This corresponds to an absolute improvement of 10% with methotrexate (95% CI 3% to 17% improvement) and a relative improvement of 30% with methotrexate (95% CI 9% to 51% improvement). </p> <p>We performed a sensitivity analysis using data for the complete case cohort (N = 128). We estimated the SD from the 95% CI reported in the supplement provided with the published manuscript. We calculated MD in HAQ scores of ‐0.20 (95% CI ‐0.42 to 0.02; <a href="./references#CD012722-fig-0040" title="">Analysis 9.2</a>). The negative sign indicates a lower HAQ score for methotrexate. This corresponds to an absolute improvement of 7% with methotrexate (95% CI 14% improvement to 1% worse) and a relative improvement of 22% with methotrexate (95% CI 47% improvement to 2% worse). </p> <p>We included results from the ITT analysis in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>. We judged the quality of the evidence to be low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0084"> <h6 class="title">Health‐related quality of life</h6> <p>Studies reported no data for this outcome.</p> </section> <section id="CD012722-sec-0085"> <h6 class="title">Disease activity</h6> <p>Only one study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) reported data for this outcome. Study authors confirmed that they used disease activity score (28 joints) with erythrocyte sedimentation rate (DAS28‐ESR; scale 0 to 10; higher scores indicate greater disease activity) as their outcome measure, and they provided unpublished data for the ITT cohort (n = 221) upon request. These included their imputed values for missing data. We estimated SD from the standard error (SE) provided by study authors. At six months, mean disease activity (DAS28‐ESR) in the placebo group was 4.1 points. We calculated an MD of ‐0.26 (95% CI ‐0.65 to 0.13; <a href="./references#CD012722-fig-0006" title="">Analysis 1.3</a>). The negative sign indicates a lower mean DAS28‐ESR score for methotrexate. This corresponds to an absolute improvement of 3% with methotrexate (95% CI 7% improvement to 1% worse) and a relative improvement of 6% with methotrexate (95% CI 16% improvement to 3% worse). </p> <p>We performed a sensitivity analysis using unpublished data for the complete case cohort (N = 128), which study authors provided upon request. We calculated an MD of ‐0.24 (95% CI ‐0.63 to 0.15; <a href="./references#CD012722-fig-0041" title="">Analysis 9.3</a>), with the negative sign indicating a lower mean DAS28‐ESR score for methotrexate. This corresponds to an absolute improvement of 2% with methotrexate (95% CI 10% improvement to 2% worse) and a relative improvement of 6% with methotrexate (95% CI 24% improvement to 4% worse). </p> <p>We included results from the ITT analysis in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>. We judged the quality of the evidence to be low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0086"> <h6 class="title">Radiographic progression</h6> <p>Studies reported no data for this outcome.</p> </section> <section id="CD012722-sec-0087"> <h6 class="title">Serious adverse events</h6> <p>Three studies reported serious adverse events (SAEs) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). Two studies reported zero SAEs at three months (<a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). For <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>, study authors provided unpublished data for the ITT cohort (N = 221) at six months upon request. </p> <p>We analysed the data using the Mantel‐Haenszel method and a random‐effects model (<a href="./references#CD012722-fig-0007" title="">Analysis 1.4</a>). For methotrexate, 1 of 141 had an SAE, and for placebo, 4 of 152 had an SAE. We calculated an RR for experiencing an SAE with methotrexate of 0.26 (95% CI 0.03 to 2.26) and an absolute risk difference of ‐0.02% (95% CI ‐0.05 to 0.01). We did not calculate the number needed to treat for an additional harmful outcome (NNTH) for this statistically non‐significant event. We found that heterogeneity was low (Chi² = 0.40; df = 2; P = 0.82; I² = 0), and we included the results of this analysis in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We performed a sensitivity analysis using a fixed‐effect model and found no variation in the results. </p> <p>Although <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a> reported no extractable adverse event data, the published manuscript describes the death of one participant following three escalating doses of intravenous methotrexate at 10‐day intervals. It is unclear in what phase this occurred (methotrexate before placebo cross‐over, or placebo before methotrexate cross‐over). Study authors could not be contacted. </p> <p>We judged the quality of evidence to be low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0088"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Three studies reported withdrawals due to adverse events (WAEs) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). Two studies reported zero WAEs at three months (<a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). </p> <p>For methotrexate, results show nine WAEs among 141 participants, and for placebo, seven WAEs among 152 participants. We analysed data using the Mantel‐Haenszel method and a random‐effects model. We calculated an RR for WAEs with methotrexate of 1.32 (95% CI 0.51 to 3.42; <a href="./references#CD012722-fig-0008" title="">Analysis 1.5</a>) and an absolute risk difference of 0.01 (95% CI ‐0.04 to 0.06). We did not calculate an NNTH for this non‐significant result. We found that heterogeneity was low (Chi² = 0.18; df = 2; P = 0.91; I² = 0), and we included the results of this analysis in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We performed a sensitivity analysis using a fixed‐effect model. We calculated an RR for WAEs with methotrexate of 1.32 (95% CI 0.51 to 3.42; <a href="./references#CD012722-fig-0008" title="">Analysis 1.5</a>) and an absolute risk difference of 0.02 (95% CI ‐0.04 to 0.07). We did not calculate an NNTH for this non‐significant result. We found that heterogeneity was low (Chi² = 0.18; df = 2; P = 0.91; I² = 0). </p> <p>We judged the quality of the evidence to be low (downgraded due to risk of bias and imprecision). </p> </section> </section> <section id="CD012722-sec-0089"> <h5 class="title">Minor outcomes (comparison 2)</h5> <section id="CD012722-sec-0090"> <h6 class="title">Disease response (American College of Rheumatology response criteria for 20% improvement (ACR20)) </h6> <p>Only one study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) reported this outcome. Study authors responded to requests for unpublished data on disease response for the ITT cohort (n = 221), which included imputed values for missing data. To communicate uncertainty in the result, they provided a mean and an SE. They did not provide absolute numbers of American College of Rheumatology response criteria for 20% improvement (ACR20) responders from the ITT cohort but provided them for the complete case cohort. ACR20 response is a dichotomous outcome (i.e. responder, non‐responder); therefore, we used complete case ACR20 responders at six months and assumed that all other participants from the ITT cohort were non‐responders. For methotrexate, 23 of 109 participants achieved ACR20 response, and for placebo, 13 of 112 achieved ACR20 response. We calculated an RR for achieving ACR20 response with methotrexate of 1.82 (95% CI 0.97 to 3.40; <a href="./references#CD012722-fig-0009" title="">Analysis 2.1</a>) and an absolute risk difference of 0.09 (95% CI 0.00 to 0.19). We did not calculate an NNTB for this result. </p> <p>We performed a sensitivity analysis using data from the complete case cohort. Study authors provided unpublished data on the number of ACR20 responders in the complete case cohort (N = 128) at six months. For methotrexate, 23 of 67 achieved ACR20 response, and for placebo, 13 of 61 achieved ACR20 response. We calculated an RR for achieving an ACR20 response with methotrexate of 1.61 (95% CI 0.90 to 2.89; <a href="./references#CD012722-fig-0042" title="">Analysis 9.4</a>) and an absolute risk difference of 0.13 (95% ‐0.02 to 0.28). We did not calculate an NNTB for this statistically non‐significant result. </p> <p>The published manuscript reported an OR for achieving an ACR20 response with methotrexate of 2.0 (95% CI 0.65 to 6.22). This was a statistically non‐significant result (P = 0.23). </p> <p>We judged the quality of the evidence to be moderate (downgraded due to imprecision).</p> </section> <section id="CD012722-sec-0091"> <h6 class="title">Enthesitis</h6> <p>Studies reported no data for this outcome.</p> </section> <section id="CD012722-sec-0092"> <h6 class="title">Dactylitis</h6> <p>Studies reported no data for this outcome.</p> </section> <section id="CD012722-sec-0093"> <h6 class="title">Pain</h6> <p>One study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) assessed pain using a visual analogue scale (VAS) (scale 0 mm to 100 mm; higher scores indicate more pain) and reported values for the ITT cohort (n = 221). These included imputed values for missing data. We estimated the SD from the 95% CI provided in the published manuscript. At six months, mean pain score in the placebo group was 38.3 mm. We calculated an MD of ‐9.5 mm (95% CI ‐16.78 mm to ‐2.22 mm; <a href="./references#CD012722-fig-0010" title="">Analysis 2.2</a>). The negative sign indicates a lower pain score with methotrexate. This corresponds to an absolute improvement of 10% with methotrexate (95% CI 2% to 17% improvement) and a relative improvement of 25% with methotrexate (95% CI 6% to 44% improvement). </p> <p>We performed a sensitivity analysis using data for the complete case cohort (N = 128). We estimated the SD from the 95% CI reported in the supplement provided with the published manuscript. We calculated an MD of ‐9.40 mm (95% CI ‐17.87 mm to ‐0.93 mm; <a href="./references#CD012722-fig-0043" title="">Analysis 9.5</a>). The negative sign indicates a lower pain score with methotrexate. This corresponds to an absolute improvement of 9% with methotrexate (95% CI 1% to 18% improvement) and a relative improvement of 25% with methotrexate (95% CI 3% to 48% improvement). </p> <p>One study (<a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>: 35 randomised participants; intramuscular methotrexate 10 mg per week (standard low‐dose oral methotrexate 15 mg per week)) assessed pain using a VAS (scale 0 mm to 100 mm; higher scores indicate more pain) and reported values for the ITT cohort (n = 35) at three months. Values reported in the manuscript were median and interquartile range (IQR). We assumed these values had a skewed distribution, and study authors did not respond to our requests for confirmation. We did not estimate the mean nor the SD. The median (IQR) was 50 mm (44) for methotrexate and 32 mm (60) for placebo (NSAIDs). We did not analyse the data further. </p> <p>A meta‐analysis was not possible. We judged the quality of the evidence to be low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0094"> <h6 class="title">Fatigue</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0095"> <h6 class="title">Skin disease</h6> <p>Only one study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) reported this outcome. Study authors provided unpublished data for the ITT cohort (n = 221) upon request. These included imputed values for missing data. We estimated the SD from the SE provided by study authors. At six months, mean skin disease (Psoriasis Area and Severity Index (PASI), scale 0 to 72; higher scores indicate greater burden of psoriasis) in the placebo group was 3.1 points. We calculated an MD of ‐0.92 (95% CI ‐1.90 to 0.06; <a href="./references#CD012722-fig-0011" title="">Analysis 2.3</a>). The negative sign indicates a lower PASI score with methotrexate, which corresponds to an absolute improvement of 1% with methotrexate (95% CI 0% to 3% improvement) and a relative improvement of 29% with methotrexate (95% CI 60% improvement to 2% worse). </p> <p>We performed a sensitivity analysis using unpublished data for the complete case cohort (N = 128) provided by study authors upon request. We calculated an MD of ‐1.38 (95% CI ‐2.69 to ‐0.07; <a href="./references#CD012722-fig-0044" title="">Analysis 9.6</a>). The negative sign indicates a lower PASI score with methotrexate, which corresponds to an absolute improvement of 2% with methotrexate (95% CI 0% to 4% improvement) and a relative improvement of 41% with methotrexate (95% CI 2% to 81% improvement). </p> <p>We judged the quality of the evidence to be low (downgraded due to indirectness and imprecision). </p> </section> <section id="CD012722-sec-0096"> <h6 class="title">Total adverse events</h6> <p>Three studies reported total adverse events (AEs) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). </p> <p>We analysed the data using the Mantel‐Haenszel method and a random‐effects model. We calculated the RR for experiencing an AE from methotrexate of 2.13 (95% CI 1.27 to 3.59; <a href="./references#CD012722-fig-0012" title="">Analysis 2.4</a>) with low heterogeneity (Chi² = 1.05; df = 1; P = 0.30; I² = 5%). The absolute risk difference was 0.21 (95% CI ‐0.17 to 0.60) (the negative sign indicates more AEs with placebo). We did not calculate the NNTH for this statistically non‐significant event, and we noted considerable heterogeneity (Chi² = 51.55; df = 2; P &lt; 0.00001; I² = 96%). </p> <p>We performed a sensitivity analysis using a fixed‐effect model. We calculated the RR for experiencing an AE from methotrexate of 2.10 (95% CI 1.68 to 2.62) with low heterogeneity (Chi² = 1.05; df = 1; P = 0.30; I² = 5%). The absolute risk difference was 0.37 (95% CI 0.28 to 0.45), and the NNTH was 3 (95% CI 2 to 3) with considerable heterogeneity (Chi² = 51.55; df = 2; P &lt; 0.00001; I² = 96%). </p> <p>We judged the quality of the evidence to be low (downgraded due to inconsistency and imprecision). </p> </section> <section id="CD012722-sec-0097"> <h6 class="title">Patient global assessment of disease activity</h6> <p>One study (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>: 221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) performed patient global assessment of disease activity on a VAS (scale 0 mm to 100 mm; higher scores indicate greater patient‐perceived global disease activity) and reported values for the ITT cohort (n = 221). These included imputed values for missing data. We estimated the SD from the 95% CI reported in the supplement provided with the published manuscript. At six months, mean patient global assessment score in the placebo group was 42.2 mm. We calculated an MD of ‐10.4 mm (95% CI ‐18.67 to ‐2.13; <a href="./references#CD012722-fig-0013" title="">Analysis 2.5</a>). The negative sign indicates a lower assessment score with methotrexate, which shows an absolute improvement of 10% with methotrexate (95% CI 2% to 19% improvement) and a relative improvement of 25% with methotrexate (95% CI 5% to 44% improvement). </p> <p>We performed a sensitivity analysis using data for the complete case cohort (N = 128). We estimated the SD using the 95% CI reported in the supplement provided with the published manuscript. We calculated an MD of ‐9.20 mm (95% CI ‐17.8 to ‐0.59; <a href="./references#CD012722-fig-0045" title="">Analysis 9.7</a>). The negative sign indicates a lower patient global assessment score with methotrexate. This corresponds to an absolute improvement of 9% with methotrexate (95% CI 1% to 18% improvement) and a relative improvement of 22% with methotrexate (95% CI 1% to 44% improvement). </p> <p><a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> reported patient global assessment of disease activity on a Likert scale from 0 to 5. Researchers reported values for the ITT cohort (n = 35) at three months as median (IQR). We assumed these values had a skewed distribution. Study authors did not respond to our requests for confirmation. We did not estimate mean nor SD. The median (IQR) was 3 (2) for methotrexate and 2 (3) for placebo (NSAIDs). We did not analyse the data further. </p> <p>We did not perform a meta‐analysis. We judged the quality of the evidence to be very low (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD012722-sec-0098"> <h6 class="title">Physician global assessment of disease activity</h6> <p><a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> (221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) performed physician global assessment of disease activity on a VAS (scale 0 to 100 mm; higher scores indicate greater physician‐perceived global disease activity) and reported values for the ITT cohort (n = 221). These included imputed values for missing data. We estimated the SD using the 95% CI from the published manuscript. At six months, the mean physician global assessment score in the placebo group was 33 mm. We calculated an MD of ‐9.70 mm (95% CI ‐15.31 to ‐4.09; <a href="./references#CD012722-fig-0014" title="">Analysis 2.6</a>). The negative sign indicates a lower physician global assessment score for methotrexate, which corresponds to an absolute improvement of 10% with methotrexate (95% CI 4% to 15% improvement) and a relative improvement of 29% with methotrexate (95% CI 12% to 46% improvement). </p> <p>We performed a sensitivity analysis for <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>, using data for the complete case analysis (N = 128). We estimated the SD from the 95% CI reported in the supplement provided with the published manuscript. We calculated an MD of ‐13.8 mm (95% CI ‐20.08 to ‐7.52; <a href="./references#CD012722-fig-0046" title="">Analysis 9.8</a>). The negative sign indicates a lower physician global assessment score for methotrexate, which corresponds to an absolute improvement of 14% with methotrexate (95% CI 8% to 20% improvement) and a relative improvement of 39% with methotrexate (95% CI 21% to 56% improvement). </p> <p><a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> performed physician global assessment of disease activity on a Likert scale of 0 to 5. They included the ITT cohort (n = 35), with values reported at three months as median (IQR). We assumed these values had a skewed distribution, and study authors did not respond to our requests for confirmation. We did not estimate mean nor SD. The median (IQR) was 3 (2) for methotrexate and 2 (3) for placebo (NSAIDs). We did not analyse the data further. </p> <p>We did not perform a meta‐analysis. We judged evidence quality to be very low (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD012722-sec-0099"> <h6 class="title">Swollen joint count</h6> <p><a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> (221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) assessed the number of swollen joints from a 66‐joint examination (scale 0 to 66; higher scores indicate more swollen joints) for the ITT cohort (n = 221). These included imputed values for missing data. We estimated the SD from the 95% CI in the published manuscript. At six months, the mean swollen joint count in the placebo group was 5.2 joints. We calculated an MD of ‐0.60 joints (95% CI ‐2.62 to 1.42; <a href="./references#CD012722-fig-0015" title="">Analysis 2.7</a>). The negative sign indicates fewer swollen joints with methotrexate, which corresponds to an absolute improvement of 1% with methotrexate (95% CI 4% improvement to 2% worse) and a relative improvement of 11% with methotrexate (95% CI 50% improvement to 27% worse). </p> <p>We performed a sensitivity analysis for <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>, using data for the complete case cohort (N = 128). We estimated the SD from the 95% CI reported in the supplement provided with the published manuscript. We calculated an MD of ‐1.4 joints (95% CI ‐4.11 to 1.31; <a href="./references#CD012722-fig-0047" title="">Analysis 9.9</a>). The negative sign indicates fewer swollen joints with methotrexate, which corresponds to an absolute improvement of 2% with methotrexate (95% CI 6% improvement to 2% worse) and a relative improvement of 25% with methotrexate (95% CI 72% improvement to 23% worse). </p> <p><a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> assessed the number of swollen joints but did not specify how many joints they examined. They reported data for the ITT cohort at three months (n = 35) as median (IQR). We assumed that these values had a skewed distribution. Study authors did not respond to our requests for confirmation. We did not estimate mean nor SD. The median (IQR) was 0 joints (1) for methotrexate and 1 joint (2) for placebo (NSAIDs). We did not analyse the data further. </p> <p>We did not perform a meta‐analysis, and we judged evidence quality to be very low (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD012722-sec-0100"> <h6 class="title">Tender joint count</h6> <p><a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> (221 randomised participants; oral methotrexate 15 mg per week (standard low‐dose)) assessed the number of tender joints from a 68‐joint examination (scale 0 to 68; higher scores indicate more tender joints) for the ITT cohort (n = 221). These included imputed values for missing data. We estimated the SD from the 95% CI provided in the published manuscript. At six months, mean tender joint count in the placebo group was 10 joints. We calculated an MD of ‐2.3 joints (95% ‐5.5 to 0.9; <a href="./references#CD012722-fig-0016" title="">Analysis 2.8</a>). The negative sign indicates fewer tender joints with methotrexate, which corresponds to an absolute improvement of 3% with methotrexate (95% CI 8% improvement to 1% worse) and a relative improvement of 23% with methotrexate (95% CI 55% improvement to 9% worse). </p> <p>We performed a sensitivity analysis for <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>, using data for the complete case cohort (N = 128). We estimated the SD from the 95% CI reported in the supplement provided with the published manuscript. We calculated an MD of ‐2.80 joints (95% CI ‐6.55 to 0.95; <a href="./references#CD012722-fig-0048" title="">Analysis 9.10</a>). The negative sign indicates fewer tender joints with methotrexate, which corresponds to an absolute improvement of 4% with methotrexate (95% CI 10% improvement to 1% worse) and a relative improvement of 26% with methotrexate (95% CI 62% improvement to 9% worse). </p> <p><a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a> assessed the number of tender joints but did not specify how many joints they examined. They reported data for the ITT cohort (n = 35) at three months as median (IQR). We assumed that these values had a skewed distribution. Study authors did not respond to our requests for confirmation. We did not estimate mean nor SD. The median (IQR) was 1 joint (1) for methotrexate and 2 joints (3) for placebo (NSAIDs). We did not analyse the data further. </p> <p>We did not perform a meta‐analysis, and we judged evidence quality to be very low (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> </section> </section> <section id="CD012722-sec-0101"> <h4 class="title">Methotrexate versus placebo (longer than six months)</h4> <p>Only one study with a placebo comparator reported outcomes beyond six months (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>). We extracted data only for WAEs and total AEs. Researchers either did not report the other outcomes in any way, or they reported the data in a format that was not extractable. We note that many of the specified outcome measures were not created until after this study was published. Study authors could not be contacted. </p> <section id="CD012722-sec-0102"> <h5 class="title">Major outcomes (comparison 3)</h5> <section id="CD012722-sec-0103"> <h6 class="title">Disease response (American College of Rheumatology response criteria for 50% improvement (ACR50), PsARC) </h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0104"> <h6 class="title">Function</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0105"> <h6 class="title">Health‐related quality of life</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0106"> <h6 class="title">Disease activity</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0107"> <h6 class="title">Radiographic progression</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0108"> <h6 class="title">Serious adverse events</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0109"> <h6 class="title">Withdrawals due to adverse events</h6> <p><a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> (72 randomised participants; oral methotrexate 10 mg per week (standard dose 15 mg per week)) reported WAEs at 12 months in the placebo (NSAIDs) arm. For methotrexate, they reported 12 WAEs among 31 participants, and for placebo, 0 WAEs among 41. We calculated the RR for WAEs due to methotrexate of 32.81 (95% CI 2.02 to 533.71; <a href="./references#CD012722-fig-0017" title="">Analysis 3.1</a>), an absolute risk difference of 0.39 (95% CI 0.21 to 0.56), and an NNTH of 3 (95% CI 3 to 5). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> </section> <section id="CD012722-sec-0110"> <h5 class="title">Minor outcomes (comparison 4)</h5> <section id="CD012722-sec-0111"> <h6 class="title">Disease response (ACR20)</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0112"> <h6 class="title">Enthesitis</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0113"> <h6 class="title">Dactylitis</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0114"> <h6 class="title">Pain</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0115"> <h6 class="title">Fatigue</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0116"> <h6 class="title">Skin disease</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0117"> <h6 class="title">Total adverse events</h6> <p><a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> (72 randomised participants; oral methotrexate 10 mg per week (standard dose 15 mg per week)) reported total AEs at 12 months in the placebo (NSAIDs) arm. For methotrexate, 17 of 31 participants experienced AEs, and for placebo, 15 of 41 experienced AEs. We calculated the RR for experiencing an AE from methotrexate of 1.50 (95% 0.90 to 2.51; <a href="./references#CD012722-fig-0018" title="">Analysis 4.1</a>) and an absolute risk difference of 0.18 (95% CI ‐0.05 to 0.41). We did not calculate an NNTH for this statistically non‐significant result. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> <section id="CD012722-sec-0118"> <h6 class="title">Patient global assessment of disease activity</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0119"> <h6 class="title">Physician global assessment of disease activity</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0120"> <h6 class="title">Swollen joint count</h6> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0121"> <h6 class="title">Tender joint count</h6> <p>Study authors reported no data for this outcome.</p> </section> </section> </section> <section id="CD012722-sec-0122"> <h4 class="title">Methotrexate versus other DMARDs (up to six months)</h4> <p>Three studies with another DMARD comparator reported outcomes up to six months (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). Not all studies reported all outcomes. We judged the overall risk of bias for both <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> and <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> to be too high to permit meaningful meta‐analysis. </p> <section id="CD012722-sec-0123"> <h5 class="title">Major outcomes (comparison 5)</h5> <section id="CD012722-sec-0124"> <h6 class="title">Disease response (ACR50, PsARC)</h6> <section id="CD012722-sec-0125"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported the number of ACR50 responders at six months. For methotrexate, results show that 12 of 14 participants were responders, and for placebo, 13 of 16 were responders. We calculated the RR for achieving an ACR50 response with methotrexate at 1.05 (95% CI 0.77 to 1.45; <a href="./references#CD012722-fig-0019" title="">Analysis 5.1</a>) and an absolute risk difference of 0.04 (95% CI ‐0.22 to 0.31). We did not calculate an NNTB for this statistically non‐significant result. </p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> also reported the number of PsARC responders at six months. For methotrexate, results show that 14 of 14 participants were responders, and for placebo, 16 of 16 were responders. We calculated an RR of 0.00 (95% CI 0.88 to 0.13; <a href="./references#CD012722-fig-0049" title="">Analysis 10.1</a>) and an absolute risk difference of 0.00 (95% CI ‐0.12 to 0.12). We did not calculate an NNTB for this statistically non‐significant result. </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported data for the number of PsARC responders; however, values reported in the written text of the published manuscript were different from those presented in the graph. We were uncertain which values were correct. Study authors did not respond to our request for clarification, and we did not extract the data. </p> <p>We included ACR50 results from <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> in <a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>. We judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0126"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0127"> <h6 class="title">Function</h6> <section id="CD012722-sec-0128"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) was the only study that used a leflunomide comparator to report this outcome. Study authors reported HAQ scores (scale 0 to 3; higher scores indicate greater disability) for the ITT cohort (n = 31). At six months, mean function in the leflunomide group was 0.17 points. We calculated a mean difference of ‐0.13 (95% CI ‐0.23 to ‐0.03; <a href="./references#CD012722-fig-0020" title="">Analysis 5.2</a>). The negative sign indicates a lower HAQ score with methotrexate. This corresponds to an absolute improvement of 4% with methotrexate (95% CI 1% to 8% improvement) and a relative improvement of 76% (95% CI 18% to 135% improvement). We included the results of this analysis in <a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0129"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0130"> <h6 class="title">Health‐related quality of life</h6> <section id="CD012722-sec-0131"> <p><b>Leflunomide</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0132"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0133"> <h6 class="title">Disease activity</h6> <section id="CD012722-sec-0134"> <p><b>Leflunomide</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0135"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0136"> <h6 class="title">Radiographic progression</h6> <section id="CD012722-sec-0137"> <p><b>Leflunomide</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0138"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0139"> <h6 class="title">Serious adverse events</h6> <section id="CD012722-sec-0140"> <p><b>Leflunomide</b></p> <p>Both <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) and <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported zero SAEs for both methotrexate and leflunomide groups. We did not perform a meta‐analysis because it was not meaningful in this circumstance. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0141"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week), oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported zero SAEs for both methotrexate and ciclosporin A groups. We judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> </section> <section id="CD012722-sec-0142"> <h6 class="title">Withdrawals due to adverse events</h6> <section id="CD012722-sec-0143"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported zero WAEs in both methotrexate and leflunomide groups. We were unable to calculate the absolute risk difference or the risk ratio. </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported WAEs at six months. For methotrexate, results show one WAE among 13 participants, and for leflunomide, two WAEs among 18. We calculated the RR for WAE for methotrexate of 0.69 (95% CI 0.07 to 6.85; <a href="./references#CD012722-fig-0022" title="">Analysis 5.4</a>) and an absolute risk difference of ‐0.03 (95% CI ‐0.24 to 0.17). We did not calculate an NNTH for this statistically non‐significant result. We included the results of this analysis in <a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>. </p> <p>We did not perform a meta‐analysis, and we judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0144"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported WAEs at six months. For methotrexate, results show four WAEs among 18 participants, and for ciclosporin A, three WAEs among 17. We calculated an RR for WAEs from methotrexate of 1.26 (95% CI 0.33 to 4.82; <a href="./references#CD012722-fig-0022" title="">Analysis 5.4</a>) and an absolute risk difference of 0.05 (95% CI ‐0.22 to 0.31). We did not calculate an NNTH for this statistically non‐significant result, and we included the results of this analysis in <a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> </section> </section> <section id="CD012722-sec-0145"> <h5 class="title">Minor outcomes (comparison 6)</h5> <section id="CD012722-sec-0146"> <h6 class="title">Disease response (ACR20)</h6> <section id="CD012722-sec-0147"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported the number of participants with a disease response. For methotrexate, the number of ACR20 responders was 14 of 14, and for leflunomide, results show 16 of 16 responders. We calculated an RR for achieving an ACR20 response with methotrexate of 1.00 (95% CI 0.88 to 1.13; <a href="./references#CD012722-fig-0023" title="">Analysis 6.1</a>) and an absolute risk difference of 0% (95% CI ‐0.12 to 0.12). We did not calculate an NNTB for this statistically non‐significant result. </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported data at six months; however, values reported in the written text were different from those presented in the graph. We were uncertain which values were correct. Study authors did not respond to our request for clarification, and we did not extract the data. </p> <p>A meta‐analysis was not possible. We judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0148"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0149"> <h6 class="title">Enthesitis</h6> <section id="CD012722-sec-0150"> <p><b>Leflunomide</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0151"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0152"> <h6 class="title">Dactylitis</h6> <section id="CD012722-sec-0153"> <p><b>Leflunomide</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0154"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0155"> <h6 class="title">Pain</h6> <section id="CD012722-sec-0156"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported pain outcomes from a VAS (scale 0 to 10 cm; higher scores indicate more pain) for the ITT cohort (n = 30). At six months, mean pain in the leflunomide group was rated as 1 cm. We calculated an MD of ‐0.07 cm (95% CI ‐0.74 to 0.60; <a href="./references#CD012722-fig-0024" title="">Analysis 6.2</a>). The negative sign indicates a lower pain score with methotrexate, which corresponds to an absolute improvement of 1% with methotrexate (95% CI 7% improvement to 6% worse) and a relative improvement of 7% with methotrexate (95% CI 74% improvement to 60% worse). </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported pain outcomes from a VAS but did not specify the length. Study authors did not respond to our request for clarification, and we made no assumptions about the scale. At six months, mean pain in the leflunomide group was 1 unit. We calculated an MD of ‐0.86 units (95% CI ‐2.19 to 0.47; <a href="./references#CD012722-fig-0024" title="">Analysis 6.2</a>). The negative sign indicates a lower pain score with methotrexate, which corresponds to a relative improvement of 30% with methotrexate (95% CI 77% improvement to 16% worse). </p> <p>We did not perform a meta‐analysis, and we judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0157"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0158"> <h6 class="title">Fatigue</h6> <section id="CD012722-sec-0159"> <p><b>Leflunomide</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0160"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0161"> <h6 class="title">Skin disease</h6> <section id="CD012722-sec-0162"> <p><b>Leflunomide</b></p> <p>Only <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported this outcome for the leflunomide subgroup, using PASI as their measure (scale 0 to 72; higher scores indicate greater burden of psoriasis) for the ITT cohort (n = 30). At six months, mean PASI score in the leflunomide group was 2.69 points. We calculated an MD of ‐0.01 (95% CI ‐1.18 to 1.16; <a href="./references#CD012722-fig-0025" title="">Analysis 6.3</a>). The negative value indicates a lower PASI score with methotrexate, which corresponds to an absolute change of 0% (95% CI 2% improvement to 2% worse) and a relative change of 0% (95% CI 44% improvement to 43% worse). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> <section id="CD012722-sec-0163"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported this outcome using PASI as their measure (scale 0 to 72; higher scores indicate greater burden of psoriasis) for the per‐protocol cohort (n = 28). At six months, mean PASI score in the ciclosporin A group was 4.2 points. We calculated an MD of ‐1.10 (95% CI ‐1.73 to ‐0.47; <a href="./references#CD012722-fig-0025" title="">Analysis 6.3</a>). The negative sign indicates a lower PASI score with methotrexate, which corresponds to an absolute improvement of 1.5% with methotrexate (95% CI 1% to 2% improvement) and a relative improvement of 26% with methotrexate (95% CI 11% to 41% improvement). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> </section> <section id="CD012722-sec-0164"> <h6 class="title">Total adverse events</h6> <section id="CD012722-sec-0165"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported total AEs at six months. For methotrexate, results show 27 AEs among 14 participants, and for leflunomide, 25 AEs among 16. We were unable to calculate an absolute risk difference or risk ratio. </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported total AEs at six months. For methotrexate, results show five AEs among 13 participants, and for leflunomide, seven AEs among 18. We calculated the RR for experiencing an AE from methotrexate of 0.99 (95% CI 0.40 to 2.43; <a href="./references#CD012722-fig-0026" title="">Analysis 6.4</a>) and an absolute risk difference of 0.00 (95% CI ‐0.35 to 0.34). We did not calculate an NNTH for this statistically non‐significant result. </p> <p>A meta‐analysis was not possible. We judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0166"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0167"> <h6 class="title">Patient global assessment of disease activity</h6> <section id="CD012722-sec-0168"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported patient global assessment of disease activity on a Likert scale (scale 1 to 5; higher scores indicate greater patient‐perceived global disease activity) for the ITT cohort (n = 30) at six months. The mean for both groups was 2, but the SD for both groups was 0. Study authors did not respond to our request for clarification. We were not able to calculate the MD nor the 95% CI. </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) did not indicate the measurement instrument used for patient global assessment of disease activity. Study authors did not respond to requests for clarification, and we made no assumptions about scale length, but we assumed that higher scores indicated greater patient‐perceived global disease activity. At six months, mean patient global assessment in the leflunomide group was 2.39 points. We calculated an MD of ‐0.96 (95% CI ‐1.64 to ‐0.28; <a href="./references#CD012722-fig-0027" title="">Analysis 6.5</a>). The negative sign indicates a lower disease activity score with methotrexate, which corresponds to a relative improvement of 40% with methotrexate (95% CI 12% to 69% improvement). </p> <p>A meta‐analysis was not possible. We judged evidence quality to be very low (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD012722-sec-0169"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported patient global assessment on a VAS (scale 0 to 100 mm; higher scores indicate greater patient‐perceived global disease activity) for the per‐protocol cohort (n = 28). At six months, the mean patient global assessment score for the ciclosporin A group was 32.8 mm. We calculated an MD of 7.20 mm (95% CI 3.16 to 11.24; <a href="./references#CD012722-fig-0027" title="">Analysis 6.5</a>), indicating a higher score for methotrexate, which corresponds to an absolute worsening of 7% with methotrexate (95% CI 3% to 11% worse) and a relative worsening of 22% with methotrexate (95% CI 10% to 34% worse). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> </section> <section id="CD012722-sec-0170"> <h6 class="title">Physician global assessment of disease activity</h6> <section id="CD012722-sec-0171"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported physician global assessment of disease activity on a Likert scale (scale 1 to 5; higher scores indicate greater physician‐perceived global disease activity) for the ITT cohort (n = 30) at six months. The mean for both groups was 2, but the SD for both groups was 0. Study authors did not respond to our request for clarification, and we did not impute the missing data. We were not able to calculate the MD nor the 95% CI. </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported physician global assessment for disease activity but did not describe the measurement instrument used. Study authors did not respond to our request for clarification, and we made no assumptions about the scale. They reported data for the ITT cohort (n = 31). At six months, the mean physician global assessment score in the leflunomide group was 2.39 points. We calculated a mean difference of ‐0.30 (95% CI ‐0.96 to 0.36; <a href="./references#CD012722-fig-0028" title="">Analysis 6.6</a>). The negative sign indicates a lower assessment score with methotrexate, which corresponds to a relative improvement of 13% with methotrexate (95% CI 40% improvement to 15% worse). </p> <p>A meta‐analysis was not possible. We judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0172"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported physician global assessment of disease activity from a VAS (scale 0 to 100 mm; higher scores indicate greater physician‐perceived global disease activity) for the per‐protocol cohort (n = 28). At six months, the mean physician global assessment score in the ciclosporin A group was 37.1 mm. We calculated a mean difference of ‐12.80 (95% CI ‐16.86 to ‐8.74; <a href="./references#CD012722-fig-0028" title="">Analysis 6.6</a>). The negative sign indicates a lower assessment score with methotrexate, which corresponds to an absolute improvement of 13% with methotrexate (95% CI 9% to 17% improvement) and a relative improvement of 35% with methotrexate (95% CI 24% to 45% improvement). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> </section> <section id="CD012722-sec-0173"> <h6 class="title">Swollen joint count</h6> <section id="CD012722-sec-0174"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported the number of swollen joints from a 66‐joint examination (scale 0 to 66; higher scores indicate more swollen joints) for the ITT cohort (n = 30). At six months, the mean swollen joint count in the leflunomide group was 0.5 joints. We calculated a mean difference of 0.14 (95% CI ‐0.36 to 0.64; <a href="./references#CD012722-fig-0029" title="">Analysis 6.7</a>). The negative sign indicates fewer swollen joints with methotrexate, which corresponds to an absolute worsening of 0.2% with methotrexate (95% CI 0.5% improvement to 1% worse) and a relative worsening of 28% with methotrexate (95% CI 72% improvement to 128% worse). </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported the number of swollen joints from a 74‐joint examination (scale 0 to 74; higher scores indicate more swollen joints) for the ITT cohort (n = 31). Study authors reported an SD of 0 for the methotrexate group. They did not respond to our request for clarification, and we were not able to calculate an MD. </p> <p>A meta‐analysis was not possible. We judged evidence quality to be very low (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0175"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) did not indicate the number of joints from their examination but reported outcomes for the per‐protocol cohort (n = 28) at six months. Study authors were not able to provide clarification. We assumed a 66‐joint count (scale 0 to 66; higher scores indicate more swollen joints) because this is the number of joints examined by <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> and <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>. At six months, the mean swollen joint count in the ciclosporin A group was 2.7 joints. We calculated an MD of ‐1.00 joints (95% CI ‐1.40 to ‐0.60; <a href="./references#CD012722-fig-0029" title="">Analysis 6.7</a>). The negative sign indicates fewer swollen joints with methotrexate, which corresponds to an absolute improvement of 1.5% with methotrexate (95% CI 1% to 2% improvement) and a relative improvement of 37% with methotrexate (95% CI 22% to 52% improvement). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> </section> <section id="CD012722-sec-0176"> <h6 class="title">Tender joint count</h6> <section id="CD012722-sec-0177"> <p><b>Leflunomide</b></p> <p><a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported the number of tender joints from a 68‐joint examination (scale 0 to 68; higher scores indicate more tender joints) for the ITT cohort (n = 30). At six months, the mean tender joint count for the leflunomide group was 1 joint. We calculated an MD of 0.33 (95% CI ‐0.36 to 1.02; <a href="./references#CD012722-fig-0030" title="">Analysis 6.8</a>). The negative sign indicates fewer tender joints with methotrexate, which corresponds to an absolute worsening of 0.5% with methotrexate (95% CI 0.5% improvement to 2% worse) and a relative worsening of 33% with methotrexate (95% CI 36% improvement to 102% worse). </p> <p><a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week); oral leflunomide 20 mg daily (standard dose)) reported the number of swollen joints from a 76‐joint examination (scale 0 to 76; higher scores indicate more tender joints) for the ITT cohort (n = 31). At six months, the mean tender joint count in the leflunomide group was three joints. We calculated an MD of ‐1.70 (95% CI ‐3.90 to 0.50; <a href="./references#CD012722-fig-0030" title="">Analysis 6.8</a>). The negative sign indicates fewer tender joints with methotrexate, which corresponds to an absolute improvement of 2% with methotrexate (95% CI 5% improvement to 1% worse) and a relative improvement of 57% with methotrexate (95% CI 130% improvement to 17% worse). </p> <p>We did not perform a meta‐analysis, and we judged evidence quality to be very low (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> <section id="CD012722-sec-0178"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) did not indicate the number of joints from their examination but reported outcomes for the per‐protocol cohort (n = 28). Study authors were not able to provide clarification. We assumed a 68‐joint count because this is the number of joints examined by <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> and <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>. At six months, mean tender joint count in the ciclosporin A group was 5.4 joints. We calculated an MD of ‐2.00 joints (95% CI ‐2.82 to ‐ 1.18; <a href="./references#CD012722-fig-0030" title="">Analysis 6.8</a>). The negative sign indicates fewer tender joints with methotrexate, which corresponds to an absolute improvement of 3% with methotrexate (95% CI 2% to 4% improvement) and a relative improvement of 37% with methotrexate (95% CI 22% to 52% improvement). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> </section> </section> </section> <section id="CD012722-sec-0179"> <h4 class="title">Methotrexate versus other DMARDs (longer than six months)</h4> <p>We identified two studies for this category (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>). Studies did not report all outcomes. In the case of <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>, study authors actually collected data for many of our specified outcomes but did not report them in an extractable way. Study authors could not be contacted or were unable to provide additional information. </p> <section id="CD012722-sec-0180"> <h5 class="title">Major outcomes (comparison 7)</h5> <section id="CD012722-sec-0181"> <h6 class="title">Disease response (ACR50, PsARC)</h6> <section id="CD012722-sec-0182"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0183"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0184"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0185"> <h6 class="title">Function</h6> <section id="CD012722-sec-0186"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0187"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0188"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0189"> <h6 class="title">Health‐related quality of life</h6> <section id="CD012722-sec-0190"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0191"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0192"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0193"> <h6 class="title">Disease activity</h6> <section id="CD012722-sec-0194"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0195"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0196"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0197"> <h6 class="title">Radiographic progression</h6> <section id="CD012722-sec-0198"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0199"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0200"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0201"> <h6 class="title">Serious adverse events</h6> <section id="CD012722-sec-0202"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported zero SAEs for both methotrexate and ciclosporin groups for the ITT cohort (n = 35) at 12 months. We were not able to calculate the absolute risk difference and the risk ratio. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0203"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0204"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0205"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Although data for WAEs could be extracted from both studies, we judged risk of bias for most domains to be uncertain or high. We believe it is less informative for results to be pooled rather than reported as individual DMARD comparators. We did not pool the data to perform a meta‐analysis. </p> <section id="CD012722-sec-0206"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported WAEs for the ITT cohort (n = 35) at 12 months. For methotrexate, five WAEs occurred in 18 participants, and for placebo, results show five WAEs among 17. We calculated the RR for WAE from methotrexate of 0.94 (95% CI 0.33 to 2.69; <a href="./references#CD012722-fig-0032" title="">Analysis 7.2</a>) and an absolute risk difference of ‐0.02 (95% CI ‐0.32 to 0.28). We did not calculate an NNTH for this statistically non‐significant result. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0207"> <p><b>Gold</b></p> <p><a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> (61 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); intramuscular gold 34 mg weekly (unclear of standard dose)) reported WAEs for the ITT cohort (n = 61) at 12 months. For methotrexate, they showed 12 WAEs among 31 participants, and for gold, 13 WAEs among 30. We calculated the RR for WAEs from methotrexate of 0.89 (95% CI 0.49 to 1.63; <a href="./references#CD012722-fig-0032" title="">Analysis 7.2</a>) and an absolute risk difference of ‐0.05 (95% CI ‐0.29 to 0.20). We did not calculate an NNTH for this statistically non‐significant result. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0208"> <p><b>Sulfasalazine</b></p> <p><a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> (55 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral sulfasalazine 1 g twice daily (standard dose)) reported WAEs for the ITT cohort (n = 55) at 12 months. For methotrexate, they show 12 WAEs among 31 participants, and for sulfasalazine, 8 WAEs among 24. We calculated the RR for WAEs from methotrexate of 1.16 (95% CI 0.57 to 2.38; <a href="./references#CD012722-fig-0032" title="">Analysis 7.2</a>) and an absolute risk difference of 0.05 (95% CI ‐0.20 to 0.31). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> </section> </section> <section id="CD012722-sec-0209"> <h5 class="title">Minor outcomes (comparison 8)</h5> <section id="CD012722-sec-0210"> <h6 class="title">Disease response (ACR20)</h6> <section id="CD012722-sec-0211"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0212"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0213"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0214"> <h6 class="title">Enthesitis</h6> <section id="CD012722-sec-0215"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0216"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0217"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0218"> <h6 class="title">Dactylitis</h6> <section id="CD012722-sec-0219"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0220"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0221"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0222"> <h6 class="title">Pain</h6> <section id="CD012722-sec-0223"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0224"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0225"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0226"> <h6 class="title">Fatigue</h6> <section id="CD012722-sec-0227"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0228"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0229"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0230"> <h6 class="title">Skin disease</h6> <section id="CD012722-sec-0231"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported effects on skin disease as measured by the PASI (scale 0 to 72; higher scores indicate greater burden of psoriasis) for the per‐protocol cohort (n = 23). At 12 months, the mean PASI score in the ciclosporin A group was 3.5 points. We calculated an MD of ‐0.60 (95% CI ‐1.43 to 0.23; <a href="./references#CD012722-fig-0033" title="">Analysis 8.1</a>). The negative sign indicates a lower PASI score with methotrexate, which corresponds to an absolute improvement of 1% with methotrexate (95% CI 2% improvement to 0.5% worse) and a relative improvement of 17% with methotrexate (95% CI 41% improvement to 7% worse). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0232"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0233"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0234"> <h6 class="title">Total adverse events</h6> <p>Although we were able to extract data for total AEs from both studies, we judged risk of bias for most domains to be uncertain or high. We believe it is less informative for results to be pooled rather than reported as individual DMARD comparators. We did not pool the data to perform a meta‐analysis. </p> <section id="CD012722-sec-0235"> <p><b>Ciclosporin A</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0236"> <p><b>Gold</b></p> <p><a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> (61 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); intramuscular gold 34 mg weekly (unclear of standard dose)) reported total AEs for the ITT cohort (n = 61) at 12 months. For methotrexate, results show 17 AEs among 31 participants, and for gold, 16 AEs among 30. We calculated the RR for experiencing an AE with methotrexate of 1.03 (95% CI 0.65 to 1.63; <a href="./references#CD012722-fig-0034" title="">Analysis 8.2</a>) and an absolute risk difference of 0.02 (95% CI ‐0.24 to 0.27). We did not calculate an NNTH for this statistically non‐significant result. </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> <section id="CD012722-sec-0237"> <p><b>Sulfasalazine</b></p> <p><a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> (55 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week); oral sulfasalazine 1 g twice daily (standard dose)) reported total AEs for the ITT cohort (n = 55) at 12 months. For methotrexate, results show 17 AEs among 31 participants, and for sulfasalazine, 8 AEs among 24. We calculated the RR for experiencing an AE with methotrexate of 1.65 (95% CI 0.86 to 3.15; <a href="./references#CD012722-fig-0034" title="">Analysis 8.2</a>) and an absolute risk difference of 0.22 (95% CI ‐0.04 to 0.47). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> </section> <section id="CD012722-sec-0238"> <h6 class="title">Patient global assessment of disease activity</h6> <section id="CD012722-sec-0239"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported patient global assessment of disease activity on a VAS (scale 0 to 100 mm; higher scores indicate greater patient‐perceived global disease activity) for the per‐protocol cohort (n = 23). At 12 months, the mean patient global assessment score in the ciclosporin A group was 27 mm. We calculated an MD of 3.00 mm (95% CI ‐0.79 to 6.79; <a href="./references#CD012722-fig-0035" title="">Analysis 8.3</a>). The negative sign indicates a lower assessment score with methotrexate, which corresponds to an absolute worsening of 3% with methotrexate (95% CI 1% improvement to 7% worse) and a relative worsening of 11% with methotrexate (95% CI 3% improvement to 25% worse). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0240"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0241"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0242"> <h6 class="title">Physician global assessment of disease activity</h6> <section id="CD012722-sec-0243"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported physician global assessment of disease activity on a VAS (scale 0 to 100 mm; higher scores indicate greater physician‐perceived global disease activity) for the per‐protocol cohort (n = 23). At 12 months, the mean physician global assessment score was 41 mm. We calculated an MD of ‐14.90 mm (95% CI ‐20.23 to ‐9.57; <a href="./references#CD012722-fig-0036" title="">Analysis 8.4</a>). The negative sign indicates a lower assessment score with methotrexate, which corresponds to an absolute improvement of 15% with methotrexate (95% CI 10% to 20% improvement) and a relative improvement of 36% with methotrexate (95% CI 23% lower to 49% lower). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0244"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0245"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0246"> <h6 class="title">Swollen joint count</h6> <section id="CD012722-sec-0247"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported the number of swollen joints but did not specify the number of joints examined. Study authors were not able to provide clarification. We assumed a 66‐joint count (scale 0 to 66; higher scores indicate more swollen joints) because this was the number of joints examined by <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> and <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>. They reported data for the per‐protocol cohort (n = 23). At 12 months, the mean swollen joint count in the ciclosporin A group was 2.5 joints. We calculated an MD of ‐1.70 joints (95% CI ‐2.21 to ‐1.19; <a href="./references#CD012722-fig-0037" title="">Analysis 8.5</a>). The negative sign indicates fewer swollen joints with methotrexate, which corresponds to an absolute improvement of 2.5% with methotrexate (95% CI 2% to 3% improvement) and a relative improvement of 68% (95% CI 48% to 88% improvement). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0248"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0249"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> <section id="CD012722-sec-0250"> <h6 class="title">Tender joint count</h6> <section id="CD012722-sec-0251"> <p><b>Ciclosporin A</b></p> <p><a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week); oral ciclosporin 3 to 5 mg/kg daily (standard dose)) reported the number of tender joints but did not specify the number of joints examined. Study authors were not able to provide clarification. We assumed a 68‐joint count (scale 0 to 68; higher scores indicate more tender joints) because this was the number of joints examined by <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> and <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>. They reported data for the per‐protocol cohort (n = 23). At 12 months, the mean tender joint count in the ciclosporin A group was 5.9 joints. We calculated an MD of ‐3.90 joints (95% CI ‐5.05 to ‐2.75; <a href="./references#CD012722-fig-0038" title="">Analysis 8.6</a>). The negative sign indicates fewer tender joints with methotrexate, which corresponds to an absolute improvement of 6% with methotrexate (95% CI 4% to 7% improvement) and a relative improvement of 66% with methotrexate (95% CI 47% to 86% improvement). </p> <p>We judged evidence quality to be very low (downgraded due to risk of bias and imprecision).</p> </section> <section id="CD012722-sec-0252"> <p><b>Gold</b></p> <p>Study authors reported no data for this outcome.</p> </section> <section id="CD012722-sec-0253"> <p><b>Sulfasalazine</b></p> <p>Study authors reported no data for this outcome.</p> </section> </section> </section> <section id="CD012722-sec-0254"> <h5 class="title">Subgroup analyses</h5> <p>We were not able to complete our planned subgroup analyses because we could not extract the required data. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012722-sec-0255" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012722-sec-0255">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012722-sec-0344">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012722-sec-0255"></div> <section id="CD012722-sec-0256"> <h3 class="title" id="CD012722-sec-0256">Summary of main results</h3> <p>We identified eight randomised controlled trials (RCTs) that assessed the benefits and safety of methotrexate for psoriatic arthritis. Five studies compared methotrexate to placebo (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>), whereas four compared methotrexate to another disease‐modifying anti‐rheumatic drug (DMARD) (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). One of these studies was a multi‐armed trial comparing placebo, methotrexate, gold, and sulfasalazine. Six studies reported outcomes up to six months, and two studies reported outcomes up to 12 months. We summarised results for major outcomes for the main comparisons in <a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012722-sec-0257"> <h4 class="title">Methotrexate versus placebo (up to six months)</h4> <section id="CD012722-sec-0258"> <h5 class="title">Summary</h5> <p>Compared with placebo, low‐quality evidence based on one trial (221 randomised participants; oral methotrexate 15 mg per week (standard low dose); <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>) suggests that methotrexate treatment might provide clinically meaningful benefit with respect to disease response (Psoriatic Arthritis Response Criteria (PsARC)), function, pain, and patient and physician global assessments of disease activity. However, trial results demonstrate no clinically important benefit with respect to disease response (American College of Rheumatology response criteria for 20% improvement (ACR20)), disease activity score (28 joints) with erythrocyte sedimentation rate (DAS28‐ESR), tender and swollen joint counts, or skin disease. </p> <p>The same trial measured health‐related quality of life but did not report the results (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). No study measured radiographic progression, enthesitis, dactylitis, or fatigue. </p> <p>It is difficult to explain why some outcomes confer benefit and others do not. We expected to see a consistent effect if true benefit was derived. One possibility is that <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> was underpowered to identify statistically significant differences. This hypothesis is supported by the fact that both function and disease response (PsARC) were sensitive to missing data (analyses using imputed data vs analyses without imputation). </p> <p>Another possibility is that methotrexate must be taken at a higher dose for a longer duration to demonstrate efficacy. <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> reached a dose of 15 mg in 78% of participants, with only 11% taking higher doses. Although use of higher doses of methotrexate may be more efficacious than use of lower doses, as suggested by <a href="./references#CD012722-bbs2-0017" title="CoatesLC , MoverleyAR , McParlandL , BrownS , Navarro‐CoyN , O'DwyerJL , et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open‐label, randomised, controlled trial. Lancet2015;386(10012):2489‐98. ">Coates 2015b</a> and <a href="./references#CD012722-bbs2-0059" title="CoatesLC , MahmoodF , EmeryP , ConaghanPG , HelliwellPS . The dynamics of response as measured by multiple composite outcome tools in the tight control of inflammation in early psoriatic arthritis (TICOPA) trial. Annals of the Rheumatic Diseases2017;76:1688‐92. [DOI: 10.1136/annrheumdis‐2017‐211137; PUBMED: 28606970] ">Coates 2017b</a>, a placebo‐controlled trial of methotrexate at these doses has not been conducted. Further limitations of <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> are discussed in the published manuscript of this trial and in a review by <a href="./references#CD012722-bbs2-0101" title="PincusT , BergmanM , YaziciY . Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?. Clinical and Experimental Rheumatology2015;33(5 Suppl 93):S82‐93. [PUBMED: 26472658] ">Pincus 2015</a>. </p> <p>Although the Pincus systematic review did not analyse whether methotrexate augments the effects of other DMARDs, several studies suggest no additional effect on disease response when DMARDs are combined with biologic DMARDs (<a href="./references#CD012722-bbs2-0053" title="AntoniCE , KavanaughA , KirkhamB , TutuncuZ , BurmesterGR , SchneiderU , et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis ‐ results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis and Rheumatism2005;52(4):1227‐36. [DOI: 10.1002/art.20967; PUBMED: 15818699] ">Antoni 2005</a>; <a href="./references#CD012722-bbs2-0086" title="KavanaughA , McInnesI , MeaseP , KruegerGG , GladmanDD , Gomez‐ReinoJ , et al. Golimumab, a new human tumour necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four‐week efficacy and safety results of a randomized, placebo‐controlled study. Arthritis and Rheumatism2009;60(4):976‐86. [DOI: 10.1002/art.24403; PUBMED: 19333944] ">Kavanaugh 2009</a>; <a href="./references#CD012722-bbs2-0087" title="KavanaughA , HusniME , HarrisonDD , KimL , LoKH , LeuJH , et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis. Arthritis and Rheumatology2017;69(11):2151‐61. [DOI: 10.1002/art.40226; PUBMED: 28805045] ">Kavanaugh 2017</a>; <a href="./references#CD012722-bbs2-0037" title="McInnesIB , MeasePJ , KirkhamB , KavanaughA , RitchlinCT , RahmanP , et al. Secukinumab, a human anti‐interleukin 17a monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet2015;386(9999):1137‐46. ">McInnes 2015</a>; <a href="./references#CD012722-bbs2-0095" title="MeasePJ , GladmanDD , RitchlinCT , RudermanEM , SteinfeldSD , ChoyEH , et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double‐blind, randomized, placebo‐controlled trial. Arthritis and Rheumatism2005;52(10):3279‐89. [DOI: 10.1002/art.21306; PUBMED: 16200601] ">Mease 2005</a>). </p> <p>Compared to placebo, low‐quality evidence based on four trials (293 randomised participants) suggests that methotrexate may be more harmful in terms of causing any adverse events, but we are uncertain if these events are more serious or lead to drug cessation (<a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). </p> </section> <section id="CD012722-sec-0259"> <h5 class="title">Major outcomes</h5> <p><a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> measured health‐related quality of life but did not report the results. No studies measured radiographic progression. </p> <p>Low‐quality evidence from one trial (221 randomised participants; oral methotrexate 15 mg per week (standard low dose)) suggests that at six months, mean function (Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ); scale 0 to 3; higher scores indicate greater disability) was rated at 1 point with placebo and 0.30 points lower (0.09 lower to 0.51 lower) with methotrexate, for an absolute improvement of 10% (3% to 17% improvement) and a relative improvement of 30% (9% improvement to 51% improvement) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). This improvement is likely to be clinically meaningful (minimum clinically important absolute difference is 0.22 points), but the 95% confidence interval (CI) includes clinically unimportant results. This imprecision limits our certainty in the results. Methotrexate might provide clinically meaningful benefit for function (<a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Low‐quality evidence from the same trial (221 randomised participants; oral methotrexate 15 mg per week (standard low dose)) suggests that at six months, mean disease activity (DAS28‐ESR; scale 0 to 10; higher scores indicate more disease activity) was 4.1 points for placebo and 0.26 points lower (0.65 lower to 0.13 higher) for methotrexate, for an absolute improvement of 3% (7% better to 1% worse) and relative improvement of 6% (16% better to 3% worse) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). The 95% CI included potential worsening of disease activity. Imprecision for this outcome limits our certainty in the results. The minimum clinically important difference for DAS28‐ESR has not been defined, but for comparison in rheumatoid arthritis, it is considered to be 1.2 points. Our results suggest that methotrexate may provide no clinically important benefit for disease activity (<a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Although disease response on ACR20 was a minor outcome, this is best interpreted through direct comparison with disease response on PsARC. Results for disease response (PsARC and ACR20; measured as responder/non‐responder, response‐benefit) show inconsistency. One trial (221 randomised participants; oral methotrexate 15 mg per week (standard low dose)) reported that more participants taking methotrexate achieved a PsARC response than those taking placebo (41/109 (or 38 per 100) with methotrexate, 24/112 (or 21 per 100) with placebo; risk ratio (RR) 1.76, 95% CI 1.14 to 2.70; absolute risk difference 0.16, 95% CI 0.04 to 0.28; number needed to treat for an additional beneficial outcome (NNTB) 6, 95% CI 4 to 25) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). Our analysis included unpublished data provided by the <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> authors (personal communication), wherein the number of responders was counted for participants who completed the study with complete data collection. We assumed that remaining participants from the intention‐to‐treat (ITT) cohort were non‐responders. Similar results were obtained in a sensitivity analysis based on complete case cohort data with no assumptions made (41/67 (or 61 per 100) for methotrexate, 24/61 (or 39 per 100) for placebo; RR 1.56, 95% CI 1.08 to 2.24; absolute risk difference 0.16, 95% CI 0.04 to 0.28; NNTB 5, 95% CI 3 to 20). The primary analysis in the published manuscript, which used a multiple imputation method for missing data, did not demonstrate a difference between methotrexate and placebo for this outcome (odds ratio (OR) 1.77, 95% CI 0.7 to 3.23). Overall, methotrexate might provide clinically meaningful benefit for disease response (PsARC), but this estimate is uncertain and is likely to be affected by further high‐quality research (<a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In contrast to the PsARC response, all analyses for ACR20 response were consistent with each other. At six months, low‐quality evidence from the same trial suggested there was no difference in ACR20 response between methotrexate (23/109 (or 21 per 100) for methotrexate) and placebo (13/112 (or 12 per 100) for placebo; RR 1.82, 95% CI 0.97 to 3.40; absolute risk difference 0.13, 95% CI 0.00 to 0.19) (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). Again, this analysis used unpublished data provided by the authors of <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> (personal communication), wherein the number of responders was counted for participants who completed the study and had a complete data collection. We assumed that remaining participants from the ITT cohort were non‐responders. This lack of benefit for disease response (ACR20) is observed when one performs a sensitivity analysis by using only data for the complete case cohort (23/67 (or 34 per 100) for methotrexate, 13/61 (or 21 per 100) for placebo; RR 1.61, 95% CI 0.90 to 2.89; absolute risk difference 0.13, 95% CI ‐0.02 to 0.28; negative sign indicates more responders with placebo), and again, in the published manuscript, which used imputed values (OR 2.0, 95% CI 0.65 to 6.22). Methotrexate might provide no clinically important benefit for disease response (ACR20). </p> <p>We downgraded evidence for disease response (PsARC and ACR20), function, and disease activity due to risk of bias and imprecision. We judged there to be potential attrition bias and reporting bias for the main study informing the results for this comparison (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). It is likely that additional data from high‐quality studies will alter the certainty of study results. </p> <p>With respect to safety, four studies ‐ <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964,</a><a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012,</a><a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008,</a> and <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a> (data from <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a> not pooled due to inability to attribute adverse events (AEs) to a treatment group) ‐ provided low‐quality evidence suggesting that methotrexate may not lead to more withdrawals due to AEs (9/141 (or 64 per 1000) for methotrexate, 7/152 (or 46 per 1000) for placebo; RR 1.32, 95% CI 0.51 to 3.42; absolute risk difference 0.01, 95% CI ‐0.04 to 0.06; the negative sign indicates more withdrawals due to adverse events (WAEs) with placebo)) or serious adverse events (SAEs) (1/141 (or 7 per 1000) for methotrexate, 4/112 (or 36 per 1000) for placebo; RR 0.26, 95% CI 0.03 to 2.26; absolute risk difference ‐0.02, 95% CI ‐0.05 to 0.01; the negative sign indicates more SAEs with placebo) (<a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Although we were unable to formally extract data from <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>, in which participants received higher‐dose intravenous (IV) methotrexate and placebo in a cross‐over design, it is notable that one participant died from complications of bone marrow failure after receiving IV methotrexate. We were unable to identify which group this participant had been assigned to before cross‐over, and so we could not include this result in our analysis. Overall, methotrexate might be more harmful than placebo when taken for up to six months (<a href="./full#CD012722-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>We downgraded the evidence for withdrawals and SAEs due to risk of bias and imprecision. We judged there to be potential attrition bias and reporting bias for the main study informing this comparison (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). The other studies were at unclear or high risk of bias for all domains (selection bias, performance bias, detection bias, attrition bias, reporting bias, other bias) (<a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). The small number of events led to imprecision. It is likely that additional data from high‐quality studies will alter the certainty of study results. </p> </section> <section id="CD012722-sec-0260"> <h5 class="title">Minor outcomes</h5> <p>No studies measured enthesitis, dactylitis, or fatigue.</p> <p>A single study (221 randomised participants; oral methotrexate 15 mg per week (standard low dose)) provided low‐quality evidence suggesting benefit of methotrexate in improving pain and patient global assessment and physician global assessment of disease activity at six months (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). Mean pain was rated at 38.3 mm on a visual analogue scale (VAS) (scale 0 to 100 mm; higher scores indicate more pain) and was rated 9.5 mm lower (2.2 mm lower to 16.8 mm lower) with methotrexate, for an absolute pain reduction of 10% (2% better to 17% better) and relative pain reduction of 25% (6% better to 44% better). Mean patient global assessment was 42.2 mm on a VAS (scale 0 to 100 mm; higher scores indicate greater perceived disease activity) with placebo and was 10.4 mm lower (2.1 mm lower to 18.7 mm lower) with methotrexate, for an absolute score that was 10% lower (2% lower to 19% lower) and a relative score that was 25% lower (5% lower to 44% lower). Mean physician global assessment was 33 mm on a VAS (scale 0 to 100 mm; higher scores indicate greater perceived disease activity) with placebo and was 9.7 mm lower (4.1 mm lower to 15.3 mm lower) with methotrexate, for an absolute score of 10% lower (4% lower to 15% lower) and relative improvement of 29% (12% lower to 46% lower). Although these results are unlikely to be clinically meaningful (minimal clinically important absolute difference is 15%), the 95% CI includes a clinically meaningful result. Imprecision for these outcomes limits our certainty in the results. Methotrexate might provide clinically meaningful benefits for pain and for patient and physician global assessments. </p> <p>At six months, the same study provided low‐quality evidence suggesting that methotrexate may be no better than placebo for tender joint count, swollen joint count, and skin disease (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). The mean tender joint count was 10 for placebo (68 joint count; 0 to 68) and was 2.3 joints lower (5.5 lower to 0.9 higher) for methotrexate, for an absolute improvement of 3% (8% better to 1% worse) and relative improvement of 23% (55% better to 9% worse). The mean swollen joint count was 5.2 for placebo (66 joint count; 0 to 66) and was 0.6 joints lower (2.6 lower to 1.4 higher) for methotrexate, for an absolute improvement of 1% (4% better to 2% worse) and relative improvement of 11% (50% better to 27% worse). Mean skin disease was 3.1 points on the PASI (0 to 72 points; lower scores indicate less psoriasis) for placebo and was 0.9 points lower (1.9 lower to 0.06 higher) for methotrexate, for an absolute improvement of 1% (0% to 3% better) and relative improvement of 29% (60% improvement to 2% worse). <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a> was not designed to assess benefits for skin disease specifically as a primary outcome. Outcome assessors may not have been as skilled in assessing skin disease with PASI, and the patient population may not have had severe skin disease from baseline. We believe skin disease could be considered in a separate review dedicated to this topic. </p> <p>With respect to adverse events, we pooled data from three studies for meta‐analysis (293 randomised participants; <a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>; <a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). We found that methotrexate was associated with more adverse events (100/149 (or 67 per 100)) when compared to placebo (49/152 (or 33 per 100)) (RR 2.13, 95% CI 1.27 to 3.59; absolute risk difference 0.21, 95% CI ‐0.17 to 0.60). For meta‐analysis, we used a random‐effects model; we did not find an absolute risk difference, primarily because each study contributed equally to the analysis and two studies (72 randomised participants) reported a total of only three adverse events for either group. We performed a sensitivity analysis using a fixed‐effect model and found different results (RR 2.10, 95% CI 1.68 to 2.62; absolute risk difference 0.37, 95% CI 0.28 to 0.45; NNTH 3, 95% CI 2 to 3). It is likely that methotrexate is poorly tolerated compared with placebo; however, imprecision for this outcome reduces our certainty in the result and is difficult to extrapolate directly to clinical practice, which has a long history of methotrexate use for this indication. </p> <p>We downgraded the evidence for adverse event outcomes due to risk of bias and imprecision. We judged there to be potential attrition bias and reporting bias for the main study informing this comparison (<a href="./references#CD012722-bbs2-0004" title="KingsleyGH , IbrahimF , ScottDI . Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate. Rheumatology (Oxford)2012;41(Suppl 3):iii89‐iii90. KingsleyGH , KowalcyzkA , TaylorH , IbrahimF , PackhamJC , McHughN , et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis and Rheumatism2010;62:664. KingsleyGH , KowalczykA , TaylorH , IbrahimF , PackhamJC , McHughNJ , et al. A randomized‐controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford)2012;51(8):1368‐77. [DOI: 10.1093/rheumatology/kes001; PUBMED: 22344657] KingsleyGH , PackhamJC , McHughNJ , MulherinDM , KitasGD , ChakravartK , et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford)2010;49(Suppl 1):i1. ">Kingsley 2012</a>). The other studies were at unclear or high risk of bias for all domains (selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias) (<a href="./references#CD012722-bbs2-0005" title="ScarpaR , PelusoR , AttenoM , MangusoF , SpanoA , IervolinoS , et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6‐month trial with methotrexate. Clinical Rheumatology2008;27(7):823‐6. [DOI: 10.1007/s10067‐007‐0787‐7; PUBMED: 18030515] ">Scarpa 2008</a>; <a href="./references#CD012722-bbs2-0007" title="WillkensRF , WilliamsHJ , WardJR , EggerMJ , ReadingJC , ClementsPJ , et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism1984;27(4):376‐81. [PUBMED: 6712754] ">Willkens 1984</a>). The small number of events led to imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> </section> <section id="CD012722-sec-0261"> <h4 class="title">Methotrexate versus placebo (beyond six months)</h4> <section id="CD012722-sec-0262"> <h5 class="title">Summary</h5> <p>No study measured disease response (PsARC or ACR20), function, health‐related quality of life, disease activity, radiographic progression, enthesitis, dactylitis, pain, fatigue, skin disease, patient or physician global assessments of disease activity, swollen or tender joint counts, or serious adverse events. Very low‐quality evidence from one study (72 randomised participants; oral methotrexate 10 mg per week (standard dose 15 mg per week) suggests that methotrexate might lead to more withdrawals than placebo beyond six months, but we are uncertain if it causes more adverse events in total (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>). </p> <p>It is important to note that this study was published before many of our outcomes of interest were formally developed and validated (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>). We downgraded the evidence due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> </section> <section id="CD012722-sec-0263"> <h4 class="title">Methotrexate versus other DMARDs (up to six months)</h4> <section id="CD012722-sec-0264"> <h5 class="title">Summary</h5> <p>Results from three studies provided very low‐quality evidence suggesting that methotrexate may be as effective as leflunomide 20 mg orally daily, and may be more effective than ciclosporin A at 3 mg to 5 mg/kg orally daily, and that participants found both drugs to be similarly tolerable (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). The two studies that compared methotrexate to leflunomide show marked differences across several risk of bias domains (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). Because of these differences, we believe it is inappropriate to pool these results, and so we analysed them separately. </p> </section> <section id="CD012722-sec-0265"> <h5 class="title">Major outcomes</h5> <section id="CD012722-sec-0266"> <h6 class="title">Leflunomide</h6> <p>No study measured health‐related quality of life, disease activity, radiographic progression, or SAEs. </p> <p>At six months, very low‐quality evidence from one trial (30 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week)) suggests there is no difference in achieving an ACR50 response (12/14 (or 86 per 100) for methotrexate, 13/16 (or 82 per 100) for placebo; RR 1.05, 95% CI 0.77 to 1.45; absolute risk difference 0.04, 95% CI ‐0.22 to 0.31; negative sign means lower response with methotrexate) (<a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>). Every participant in both groups in the same study achieved an ACR20 response (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>). Given the low‐quality evidence on methotrexate versus placebo at this same time point for disease response (ACR20), we are uncertain if this result is accurate. We believe this result should not be used to inform clinical practice. </p> <p>At six months in one trial (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week (standard low dose is 15 mg per week)); mean function (HAQ score) was 0.17 points with leflunomide (scale 0 to 3; 0 = no functional impairment) and was 0.13 points lower (0.23 lower to 0.03 lower) with methotrexate, for an absolute improvement of 4% (1% better to 8% better) and relative improvement of 76% (18% better to 135% better) (<a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). This reduction is not likely to be clinically meaningful (minimal clinically important absolute difference is 0.22 points), but the 95% CI includes a meaningful result, and this imprecision limits our certainty in the results. We are uncertain whether methotrexate is better than leflunomide in improving function (<a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>). </p> <p>One trial (30 randomised participants; oral methotrexate 10 mg per week) reported zero withdrawals due to adverse events, and so we are uncertain of the true direction or magnitude of the effect (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>). Very low‐quality evidence from the other trial (31 randomised participants; oral methotrexate 7.5 mg to 25 mg per week) suggests that withdrawals may not be increased with methotrexate (1/13 (or 8 per 100) with methotrexate, 2/18 (or 11 per 100) with placebo; RR 0.69, 95% CI 0.07 to 6.85; absolute risk difference ‐0.03, 95% CI ‐0.24 to 0.17; negative sign indicates less harm with methotrexate) (<a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). </p> <p>We downgraded the evidence for all outcomes due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> <section id="CD012722-sec-0267"> <h6 class="title">Ciclosporin A</h6> <p>Trials provided no data for disease response (PsARC, ACR50), function, health‐related quality of life, disease activity, or radiographic progression. </p> <p>Very low‐quality evidence from one trial (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week)) suggests that it is uncertain whether methotrexate is more harmful than ciclosporin A (3 mg to 5 mg/kg orally daily) (<a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>). This study reported zero SAEs, and we are uncertain of the direction and magnitude of the true effect. Based on very low‐quality evidence from the same study, we are uncertain if methotrexate leads to more withdrawals when compared with ciclosporin A (4/18 (or 22 per 100) with methotrexate, 3/17 (or 18 per 100) with placebo; RR 1.26, 95% CI ‐0.33 to 4.82; absolute risk difference 0.05, 95% CI ‐0.22 to 0.31; negative sign indicates less harm with methotrexate) (<a href="./full#CD012722-tbl-0002">summary of findings Table 2</a>). </p> <p>It is important to note that this study ‐ <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> ‐ was published before many of the outcomes of interest in our systematic review were formally developed and validated. We downgraded the evidence for all outcomes due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> </section> <section id="CD012722-sec-0268"> <h5 class="title">Minor outcomes</h5> <section id="CD012722-sec-0269"> <h6 class="title">Leflunomide</h6> <p>Very low‐quality evidence from one study suggests that methotrexate might lead to greater improvement in patient global assessment of disease activity (<a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>), but it is unclear which scale researchers used, and we are not able to clarify this with the study authors. Two studies provided very low‐quality evidence suggesting that there are no between‐group differences for disease response (ACR20), pain, skin disease, physician global assessment of disease activity, swollen and tender joint counts, and total AEs (<a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a>; <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>). Researchers provided no data for enthesitis, dactylitis, or fatigue. </p> <p>We downgraded the evidence for all outcomes due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> <section id="CD012722-sec-0270"> <h6 class="title">Ciclosporin A</h6> <p>No data show measurements for enthesitis, dactylitis, pain, fatigue, or total AEs.</p> <p>Compared with ciclosporin A, very low‐quality evidence based on one trial (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week)) suggests that methotrexate might provide clinically meaningful benefit with respect to physician global assessment but no clinically meaningful benefit for skin disease, patient global assessment, swollen joint count, or tender joint count (<a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>). </p> <p>It is important to note that this study ‐ <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> ‐ was published before many of our outcomes of interest were formally developed and validated. We downgraded the evidence for all outcomes due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> </section> </section> <section id="CD012722-sec-0271"> <h4 class="title">Methotrexate versus other DMARDs (beyond six months)</h4> <section id="CD012722-sec-0272"> <h5 class="title">Summary</h5> <section id="CD012722-sec-0273"> <h6 class="title">Ciclosporin A</h6> <p>Researchers have provided no data for disease response (ACR50, PsARC, ACR20), function, health‐related quality of life, disease activity, radiographic progression, enthesitis, dactylitis, pain, fatigue, and total adverse events. </p> <p>Compared with ciclosporin A (oral ciclosporin 3 mg to 5 mg/kg daily), very low‐quality evidence based on one trial (35 randomised participants; oral methotrexate 7.5 mg to 15 mg per week (standard low dose is 15 mg per week)) suggests that beyond six months, methotrexate might provide clinically meaningful benefit with respect to physician global assessment (<a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a>). <a href="./references#CD012722-bbs2-0006" title="SpadaroA , RiccieriV , Sili‐ScavalliA , SensiF , TaccariE , ZoppiniA . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study. Clinical and Experimental Rheumatology1995;13(5):589‐93. [PUBMED: 8575136] ">Spadaro 1995</a> also indicates there may be no clinically meaningful benefit for swollen joint count, tender joint count, skin disease, or patient global assessment; these study authors reported zero serious adverse events for both groups, and we are uncertain of the true magnitude or direction of effect for this outcome. </p> <p>We downgraded the evidence for both outcomes due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> <section id="CD012722-sec-0274"> <h6 class="title">Gold and sulfasalazine</h6> <p>We found inadequate evidence to inform how methotrexate compares to either sulfasalazine or gold therapy beyond six months with respect to disease response (ACR50, PsARC, ACR20), function, health‐related quality of life, disease activity, radiographic progression, enthesitis, dactylitis, pain, fatigue, skin disease, patient and physician global assessments, tender and swollen joint counts, and serious adverse events. </p> <p>Very low‐quality evidence from one trial (61 randomised participants; oral methotrexate 10 mg per week (standard low dose is 15 mg per week)) limits our certainty about whether methotrexate leads to more withdrawals due to adverse events or total adverse events than gold (intramuscular gold 34 mg per week) (<a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a>). </p> <p>Researchers studied no other DMARDs beyond six months.</p> <p>It is important to note that this study ‐ <a href="./references#CD012722-bbs2-0003" title="BurdeinyiAP , AgababovaER , KorotaevaTV , Kharamil'oLF . The comparative efficacy of slow‐acting (basic) preparations in psoriatic arthritis. Terapevticheskii Arkhiv1992;64(5):54‐9. [PUBMED: 1360714] ">Burdeinyi 1992</a> ‐ was published before many of our outcomes of interest were formally developed and validated. We downgraded the evidence for both adverse event outcomes for both sulfasalazine and gold groups due to potential risk of bias (selection bias, performance bias, detection bias, attrition bias, and reporting bias), indirectness, and imprecision. It is likely that additional data from high‐quality studies will alter the certainty of these results. </p> </section> </section> </section> </section> <section id="CD012722-sec-0275"> <h3 class="title" id="CD012722-sec-0275">Overall completeness and applicability of evidence</h3> <p>Overall we found that researchers have not addressed a large number of outcomes, and this review remains incomplete as a consequence. All study participants had psoriatic arthritis with peripheral disease, although disease severity varied and findings may not apply to all patients encountered in clinical practice. Doses of methotrexate were generally low, and some clinicians may use higher doses internationally. The effect of higher‐dose methotrexate compared to placebo remains unknown. With the exception of the primary comparison (methotrexate vs placebo up to six months), researchers reported very low numbers of adverse events, particularly serious adverse events. This is likely to lead to inaccurate estimations of the safety of methotrexate. </p> </section> <section id="CD012722-sec-0276"> <h3 class="title" id="CD012722-sec-0276">Quality of the evidence</h3> <p>According to the GRADE Working Group, we applied the following grades when assessing evidence: high‐quality evidence indicates high confidence that the true effect lies close to that of the estimate of the effect; moderate‐quality evidence indicates moderate confidence in the effect estimate (i.e. the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); low‐quality evidence indicates that confidence in the effect estimate is limited (i.e. the true effect may be substantially different from the estimate of the effect); and very low‐quality evidence suggests very little confidence in the effect estimate (i.e. the true effect is likely to be substantially different from the estimate of effect). Using the GRADE approach, we judged the quality of evidence for each outcome and each comparison and provided reasons as follows. </p> <section id="CD012722-sec-0277"> <h4 class="title">Methotrexate versus placebo (up to six months)</h4> <section id="CD012722-sec-0278"> <h5 class="title">Major outcomes</h5> <p>For outcomes of disease response (PsARC), function, disease activity (DAS28‐ESR), serious adverse events, and withdrawals due to adverse events, results were informed by low‐quality evidence (downgraded due to risk of bias and imprecision). Study authors did not report health‐related quality of life and did not measure radiographic progression. </p> </section> <section id="CD012722-sec-0279"> <h5 class="title">Minor outcomes</h5> <p>For outcomes of disease response (ACR20), pain, skin disease (PASI), and total adverse events, results were informed by low‐quality evidence (downgraded due to risk of bias and imprecision). Researchers did not measure enthesitis, dactylitis, and fatigue. For outcomes of patient and physician global assessments of disease activity, and tender and swollen joint counts, results were informed by very low‐quality evidence (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> </section> <section id="CD012722-sec-0280"> <h4 class="title">Methotrexate versus placebo (beyond six months)</h4> <section id="CD012722-sec-0281"> <h5 class="title">Major outcomes</h5> <p>For outcomes of disease response (PsARC), function, health‐related quality of life, disease activity, radiographic progression, and serious adverse events, study authors did not provide results. Withdrawal due to adverse events was informed by very low‐quality evidence, downgraded due to risk of bias, indirectness, and imprecision. </p> </section> <section id="CD012722-sec-0282"> <h5 class="title">Minor outcomes</h5> <p>For outcomes of disease response (ACR20), enthesitis, dactylitis, pain, fatigue, skin disease (PASI), patient and physician global assessments of disease activity, and swollen and tender joint counts, study authors did not report results. Total adverse events was informed by very low‐quality evidence, downgraded due to risk of bias, indirectness, and imprecision. </p> </section> </section> <section id="CD012722-sec-0283"> <h4 class="title">Methotrexate versus other DMARDs (up to six months)</h4> <section id="CD012722-sec-0284"> <h5 class="title">Major outcomes</h5> <p>For outcomes of disease response (PsARC), function, serious adverse events, and withdrawals due to adverse events, results were informed by very low‐quality evidence (downgraded due to risk of bias and imprecision). For outcomes of health‐related quality of life, disease activity, and radiographic progression, trials provided no results. </p> </section> <section id="CD012722-sec-0285"> <h5 class="title">Minor outcomes</h5> <p>For outcomes of disease response (ACR20), pain, and skin disease (PASI), results were informed by very low‐quality evidence (downgraded due to risk of bias and imprecision). For outcomes of enthesitis, dactylitis, and fatigue, trial authors did not report results. For outcomes of total adverse events, patient and physician global assessments of disease activity, and swollen and tender joint counts, results were informed by very low‐quality evidence (downgraded due to risk of bias, inconsistency, and imprecision). </p> </section> </section> <section id="CD012722-sec-0286"> <h4 class="title">Methotrexate versus other DMARDs (beyond six months)</h4> <section id="CD012722-sec-0287"> <h5 class="title">Major outcomes</h5> <p>For outcomes of disease response (PsARC), function, health‐related quality of life, disease activity, and radiographic progression, trials did not report results. For outcomes of serious adverse events and withdrawals due to adverse events, results were informed by very low‐quality evidence (downgraded due to risk of bias and imprecision). </p> </section> <section id="CD012722-sec-0288"> <h5 class="title">Minor outcomes</h5> <p>For outcomes of disease response (ACR20), enthesitis, dactylitis, pain, and fatigue, study authors did not provide results. For outcomes of skin disease (PASI), total adverse events, patient and physician global assessments of disease activity, and swollen and tender joint counts, results were informed by very low‐quality evidence (downgraded due to risk of bias, indirectness, and imprecision). </p> </section> </section> </section> <section id="CD012722-sec-0289"> <h3 class="title" id="CD012722-sec-0289">Potential biases in the review process</h3> <p>For this review, we searched Embase, MEDLINE and the Cochrane Library without language restrictions and identified eight relevant studies. It is always possible to identify additional studies by expanding the search to more databases. We are not aware of any other potential biases in the review process. </p> </section> <section id="CD012722-sec-0290"> <h3 class="title" id="CD012722-sec-0290">Agreements and disagreements with other studies or reviews</h3> <p>The previous Cochrane systematic review on this topic concluded that parenteral high‐dose methotrexate was effective for psoriatic arthritis, and that oral low‐dose methotrexate may be effective but requires further multi‐centre clinical trials to establish its efficacy (<a href="./references#CD012722-bbs2-0085" title="JonesG , CrottyM , BrooksP . Interventions for treating psoriatic arthritis. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD000212] ">Jones 2000</a>). The authors of the present review do not uniformly agree with these conclusions. With respect to high‐dose methotrexate, we were unable to extract data from <a href="./references#CD012722-bbs2-0002" title="BlackRL , O'BrienWM , VanScottEJ , AuerbackR , EizenAZ , BunimJJ . Methotrexate therapy in psoriatic arthritis: double‐blind study on 21 patients. Journal of the American Medical Association1964;189:743‐7. [PUBMED: 14174051] ">Black 1964</a>. Despite this, use of high‐dose parenteral methotrexate (up to 150 mg) was shown to be potentially lethal (one patient died from complications of bone marrow failure); therefore, we conclude that this treatment is unlikely to be useful in the management of psoriatic arthritis. With respect to low‐dose methotrexate, several additional studies have been published since <a href="./references#CD012722-bbs2-0085" title="JonesG , CrottyM , BrooksP . Interventions for treating psoriatic arthritis. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD000212] ">Jones 2000</a> was prepared. Upon inclusion of these studies, we conclude that oral low‐dose methotrexate is not definitively more effective than placebo, although the estimate of effects may be altered by additional large high‐quality trials. </p> <p>Methotrexate is commonly recommended in international guidelines as first‐line DMARD therapy for patients with peripheral arthritis (<a href="./references#CD012722-bbs2-0057" title="CoatesLC , KavanaughA , MeasePJ , SorianoER , Laura Acosta‐FelquerM , AmstrongAW , et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis and Rheumatology2016;68(5):1060‐71. [DOI: 10.1002/art.39573; PUBMED: 26749174] ">Coates 2016b</a>; <a href="./references#CD012722-bbs2-0075" title="GossecL , SmolenJS , RamiroS , deWitM , CutoloM , DougadosM , et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases2016;75(3):499‐510. [PUBMED: 26644232] ">Gossec 2016</a>). <a href="./references#CD012722-bbs2-0058" title="CoatesLC , GossecL , RamiroS , MeaseP , van derHeijdeD , SmolenJS , et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford)2017;56(8):1251‐3. [DOI: 10.1093/rheumatology/kew390; PUBMED: 28077693] ">Coates 2017a</a> explains that the persistence of recommending methotrexate in international guidelines is due to its apparent benefit reported by observational trials and the positive expert experience reported. Our systematic review does not provide definitive support for the superiority of methotrexate over placebo. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012722-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012722-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012722-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012722-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 1 Disease response (PsARC)." data-id="CD012722-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 1 Disease response (PsARC). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 2 Function (HAQ)." data-id="CD012722-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 2 Function (HAQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 3 Disease activity (DAS28‐ESR)." data-id="CD012722-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 3 Disease activity (DAS28‐ESR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 4 Serious adverse events." data-id="CD012722-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 4 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 5 Withdrawals due to adverse events." data-id="CD012722-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Methotrexate versus placebo – major outcomes ≤ 6 months, Outcome 5 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 1 Disease response (ACR20)." data-id="CD012722-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 1 Disease response (ACR20). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 2 Pain." data-id="CD012722-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 2 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 3 Skin disease (PASI)." data-id="CD012722-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 3 Skin disease (PASI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 4 Total adverse events." data-id="CD012722-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 4 Total adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 5 Patient global assessment of disease activity." data-id="CD012722-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 5 Patient global assessment of disease activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 6 Physician global assessment of disease activity." data-id="CD012722-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 6 Physician global assessment of disease activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 7 Swollen joint count." data-id="CD012722-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 7 Swollen joint count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 8 Tender joint count." data-id="CD012722-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Methotrexate versus placebo – minor outcomes ≤ 6 months, Outcome 8 Tender joint count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Methotrexate versus placebo ‐ major outcomes &gt; 6 months, Outcome 1 Withdrawals due to adverse events." data-id="CD012722-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Methotrexate versus placebo ‐ major outcomes &gt; 6 months, Outcome 1 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Methotrexate versus placebo ‐ minor outcomes &gt; 6 months, Outcome 1 Total adverse events." data-id="CD012722-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Methotrexate versus placebo ‐ minor outcomes &gt; 6 months, Outcome 1 Total adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 1 Disease response (ACR50)." data-id="CD012722-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 1 Disease response (ACR50). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 2 Function (HAQ)." data-id="CD012722-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 2 Function (HAQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 3 Serious adverse events." data-id="CD012722-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 4 Withdrawals due to adverse events." data-id="CD012722-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Methotrexate versus other DMARDs – major outcomes ≤ 6 months, Outcome 4 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 1 Disease response (ACR20)." data-id="CD012722-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 1 Disease response (ACR20). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 2 Pain." data-id="CD012722-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 2 Pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 3 Skin disease." data-id="CD012722-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 3 Skin disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 4 Total adverse events." data-id="CD012722-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 4 Total adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 5 Patient global assessment of disease activity." data-id="CD012722-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 5 Patient global assessment of disease activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 6 Physician global assessment of disease activity." data-id="CD012722-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 6 Physician global assessment of disease activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 7 Swollen joint count." data-id="CD012722-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 7 Swollen joint count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 8 Tender joint count." data-id="CD012722-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Methotrexate versus other DMARDs – minor outcomes ≤ 6 months, Outcome 8 Tender joint count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Methotrexate versus other DMARDs ‐ major outcomes &gt; 6 months, Outcome 1 Serious adverse events." data-id="CD012722-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Methotrexate versus other DMARDs ‐ major outcomes &gt; 6 months, Outcome 1 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Methotrexate versus other DMARDs ‐ major outcomes &gt; 6 months, Outcome 2 Withdrawals due to adverse events." data-id="CD012722-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Methotrexate versus other DMARDs ‐ major outcomes &gt; 6 months, Outcome 2 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 1 Skin disease." data-id="CD012722-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 1 Skin disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 2 Total adverse events." data-id="CD012722-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 2 Total adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 3 Patient global assessment of disease activity." data-id="CD012722-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 3 Patient global assessment of disease activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 4 Physician global assessment of disease activity." data-id="CD012722-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 4 Physician global assessment of disease activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 5 Swollen joint count." data-id="CD012722-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 5 Swollen joint count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 6 Tender joint count." data-id="CD012722-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months, Outcome 6 Tender joint count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 1 Disease response (PsARC) ‐ sensitivity analysis." data-id="CD012722-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 1 Disease response (PsARC) ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 2 Function (HAQ) ‐ sensitivity analysis." data-id="CD012722-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 2 Function (HAQ) ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 3 Disease activity (DAS28‐ESR) ‐ sensitivity analysis." data-id="CD012722-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 3 Disease activity (DAS28‐ESR) ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 4 Disease response (ACR20) ‐ sensitivity analysis." data-id="CD012722-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 4 Disease response (ACR20) ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 5 Pain ‐ sensitivity analysis." data-id="CD012722-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 5 Pain ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 6 Skin disease ‐ sensitivity analysis." data-id="CD012722-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 6 Skin disease ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 7 Patient global assessment of disease activity ‐ sensitivity analysis." data-id="CD012722-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 7 Patient global assessment of disease activity ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 8 Physician global assessment of disease activity ‐ sensitivity analysis." data-id="CD012722-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 8 Physician global assessment of disease activity ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 9 Swollen joint count ‐ sensitivity analysis." data-id="CD012722-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 9 Swollen joint count ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 10 Tender joint count ‐ sensitivity analysis." data-id="CD012722-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Methotrexate versus placebo ≤ 6 months (sensitivity analysis), Outcome 10 Tender joint count ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012722-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/urn:x-wiley:14651858:media:CD012722:CD012722-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_t/tCD012722-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Additional analysis – methotrexate versus other DMARDs ≤ 6 months, Outcome 1 Disease response (PsARC)." data-id="CD012722-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Additional analysis – methotrexate versus other DMARDs ≤ 6 months, Outcome 1 Disease response (PsARC). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/media/CDSR/CD012722/image_n/nCD012722-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012722-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methotrexate compared to placebo for psoriatic arthritis (up to six months)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methotrexate compared to placebo for psoriatic arthritis (up to six months)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriatic arthritis<br/> <b>Setting:</b> rheumatology clinics (outpatient setting)<br/> <b>Intervention:</b> methotrexate (oral ≤ 15 mg per week)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methotrexate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease response<br/> assessed with PsARC (response event indicates improvement)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>377 per 1000<br/> (244 to 579) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.76<br/> (1.14 to 2.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 16% more responded to treatment with methotrexate (4% more to 28% more); relative change ‐ 76% more responded to treatment with methotrexate (14% more to 170% more) </p> <p>NNTB 6 (5 to 25)</p> <p>When using imputed values, study authors calculated OR 1.77 (95% CI 0.97 to<br/> 3.23)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Function<br/> assessed with HAQ<br/> Scale from 0 to 3 (0 shows no functional impairment)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HAQ score was 1.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean difference in HAQ score was 0.3 lower<br/> (0.51 lower to 0.09 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute change ‐ 10% better with methotrexate (3% better to 17% better); relative change ‐ 30% with methotrexate (95% CI 9% to 51% improvement)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured in one study but reported as abstract only; data for extraction could not be obtained (personal communication) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease activity<br/> assessed with DAS28‐ESR<br/> Scale from: 0 to 10 (0 shows no disease activity)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean DAS28‐ESR was 4.06</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean difference in DAS28‐ESR was 0.26 lower<br/> (0.65 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement ‐ 3% better with methotrexate (7% better to 1% worse); relative improvement ‐ 6% better with methotrexate (16% better to 3% worse)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiographic progression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (SAEs)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/> (0.03 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 2% fewer events with methotrexate (5% fewer to 1% more); relative difference ‐ 74% fewer (97% fewer to 116% more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events (WAEs) assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/> (23 to 158) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.32<br/> (0.51 to 3.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 1% more events with methotrexate (4% fewer to 6% more); relative difference ‐ 32% more events with methotrexate (49% fewer to 242% more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; DAS28‐ESR: disease activity score (28 joints) with erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire for Rheumatoid Arthritis; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; PsARC: Psoriatic Arthritis Response Criteria; RCT: randomised controlled trial; RR: risk ratio; SAEs: serious adverse events; WAEs: withdrawals due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to risk of bias: judged as unclear or high risk in at least one study. </p> <p><sup>b</sup>Downgraded due to imprecision: low numbers of events with confidence intervals including potentially clinically meaningless benefits. </p> <p><sup>c</sup>Study authors did not report summary data from the ITT population. We assumed that missing participants had no response, and we calculated the ITT analysis using the number randomised. </p> <p><sup>d</sup>Relative changes calculated as absolute change (mean difference) divided by mean at baseline in the placebo group (values were 1.0 on 0 to 3 HAQ; 4.06 on 0 to 10 DAS28‐ESR). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methotrexate compared to placebo for psoriatic arthritis (up to six months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012722-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriatic arthritis<br/> <b>Setting:</b> rheumatology clinics (outpatient setting)<br/> <b>Intervention:</b> methotrexate (oral 7.5 mg to 25 mg per week)<br/> <b>Comparison:</b> other DMARDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other DMARDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methotrexate (any dose)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease response (leflunomide)<br/> assessed with ACR50<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>813 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>853 per 1000<br/> (626 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05<br/> (0.77 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute difference ‐ 4% more responders with methotrexate (22% fewer to 31% more); relative change ‐ 5% more responders (23% fewer to 45% more). NNTB not calculated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Function (leflunomide)<br/> assessed with HAQ<br/> Scale from 0 to 3<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HAQ score for leflunomide was 0.17</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean difference in HAQ score for leflunomide was 0.13 lower<br/> (0.23 lower to 0.03 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement ‐ 4% better with methotrexate (1% better to 8% better); relative improvement ‐ 76% better with methotrexate (18% to 135% improvement)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured by any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease activity ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured by any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiographic progression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured by any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (leflunomide)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference and risk ratio could not be calculated due to zero events in both arms. Direction and magnitude of the true effect remain uncertain </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events (leflunomide)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Of the 2 included studies, <a href="./references#CD012722-bbs2-0001" title="AsaduzzamanAT , SikderA , MahmudMM , PaulHK , IslamMN . Efficacy and safety of leflunomide in psoriatic arthritis. Journal of the Pakistan Association of Dermatology2014;24(1):51‐6. ">Asaduzzaman 2014</a> had zero events in both groups ‐ absolute and relative risks could not be calculated. In <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>, the ratio of events to total number of participants per group was 1/13 for methotrexate and 2/18 for leflunomide. RR 0.69 (95% CI 0.07 to 6.85). Comments apply to <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a> only </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For <a href="./references#CD012722-bbs2-0008" title="ZhangGL , HuangF , ZhangJL , LiXF . A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi2009;48(7):570‐4. [PUBMED: 19957798] ">Zhang 2009</a>: absolute risk difference ‐ 3% lower than leflunomide (95% CI 24% lower to 17% higher); risk ratio ‐ 31% lower than leflunomide (95% CI 93% lower to 585% higher). NNTH not calculated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (ciclosporin A)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference and risk ratio could not be calculated due to zero events in both arms. Direction and magnitude of the true effect remain uncertain </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events (ciclosporin A)<br/> assessed by number of events<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000<br/> (58 to 851) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.26<br/> (0.33 to 4.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference ‐ 5% higher than ciclosporin A (95% CI 22% lower to 31% higher); risk ratio ‐ 26% higher than ciclosporin A (95% CI 67% lower to 382% higher). NNTH not calculated </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ACR50: American College of Rheumatology response criteria for 50% improvement; CI: confidence interval; DMARDs: disease‐modifying anti‐rheumatic drugs; HAQ: Health Assessment Questionnaire for Rheumatoid Arthritis; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SAEs: serious adverse events; WAEs: withdrawals due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to risk of bias: judged as unclear or high in at least one domain and at least one study. </p> <p><sup>b</sup>Downgraded twice due to imprecision: low numbers of events with confidence intervals including potentially clinically meaningless benefits. </p> <p><sup>c</sup>Relative changes calculated as absolute change (mean difference) divided by mean at baseline in the placebo group (values were 0.17 on 0 to 3 HAQ). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/full#CD012722-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methotrexate versus placebo – major outcomes ≤ 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease response (PsARC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function (HAQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Disease activity (DAS28‐ESR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.51, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methotrexate versus placebo – major outcomes ≤ 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Methotrexate versus placebo – minor outcomes ≤ 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease response (ACR20) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Skin disease (PASI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.27, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Patient global assessment of disease activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Physician global assessment of disease activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Swollen joint count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Tender joint count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Methotrexate versus placebo – minor outcomes ≤ 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Methotrexate versus placebo ‐ major outcomes &gt; 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Methotrexate versus placebo ‐ major outcomes &gt; 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Methotrexate versus placebo ‐ minor outcomes &gt; 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Methotrexate versus placebo ‐ minor outcomes &gt; 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Methotrexate versus other DMARDs – major outcomes ≤ 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease response (ACR50) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Leflunomide (ACR50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function (HAQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Methotrexate versus other DMARDs – major outcomes ≤ 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Methotrexate versus other DMARDs – minor outcomes ≤ 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease response (ACR20) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Skin disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Patient global assessment of disease activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Physician global assessment of disease activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Swollen joint count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Tender joint count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Leflunomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Methotrexate versus other DMARDs – minor outcomes ≤ 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Methotrexate versus other DMARDs ‐ major outcomes &gt; 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Gold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sulfasalazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Methotrexate versus other DMARDs ‐ major outcomes &gt; 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Skin disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Gold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sulfasalazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Patient global assessment of disease activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Physician global assessment of disease activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Swollen joint count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Tender joint count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Ciclosporin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Methotrexate versus other DMARDs ‐ minor outcomes &gt; 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Methotrexate versus placebo ≤ 6 months (sensitivity analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease response (PsARC) ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function (HAQ) ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Disease activity (DAS28‐ESR) ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Disease response (ACR20) ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pain ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Skin disease ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Patient global assessment of disease activity ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Physician global assessment of disease activity ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Swollen joint count ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Tender joint count ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Methotrexate versus placebo ≤ 6 months (sensitivity analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012722-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Additional analysis – methotrexate versus other DMARDs ≤ 6 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease response (PsARC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Leflunomide (PsARC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Additional analysis – methotrexate versus other DMARDs ≤ 6 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012722.pub2/references#CD012722-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012722.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012722-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012722-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012722-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD012722-note-0011">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD012722-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012722-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012722-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012722\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012722\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012722\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012722\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012722\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012722.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012722.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012722.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012722.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012722.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729675878"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012722.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729675882"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012722.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee2afaa7a9377',t:'MTc0MDcyOTY3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 